

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization

International Bureau

(43) International Publication Date  
02 March 2023 (02.03.2023)



(10) International Publication Number  
**WO 2023/025617 A1**

(51) International Patent Classification:

C07D 401/14 (2006.01) A01N 43/653 (2006.01)  
C07D 403/04 (2006.01)

(21) International Application Number:

PCT/EP2022/072821

(22) International Filing Date:

16 August 2022 (16.08.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

21193535.8 27 August 2021 (27.08.2021) EP  
21193536.6 27 August 2021 (27.08.2021) EP  
21215019.7 16 December 2021 (16.12.2021) EP

(71) Applicant: **BASF SE** [DE/DE]; Carl-Bosch-Strasse 38,  
67056 Ludwigshafen (DE).

(72) Inventors: **HUWYLER, Nikolas**; Carl-Bosch-Strasse 38,  
67056 Ludwigshafen (DE). **KOERBER, Karsten**; Carl-  
Bosch-Strasse 38, 67056 Ludwigshafen (DE). **PEDRONI,  
Julia**; Carl-Bosch-Strasse 38, 67056 Ludwigshafen (DE).  
**GILBERG, Erik**; Maastrichter Strasse 23, 50672 Köln  
(DE).

(74) Agent: **BASF IP ASSOCIATION**; BASF SE GBI - C006,  
67056 Ludwigshafen (DE).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,  
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,  
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,  
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,  
LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA,  
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,  
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,  
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,  
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,  
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,  
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
KM, ML, MR, NE, SN, TD, TG).


**Declarations under Rule 4.17:**

- as to applicant's entitlement to apply for and be granted a  
patent (Rule 4.17(ii))
- of inventorship (Rule 4.17(iv))

**Published:**

- with international search report (Art. 21(3))

(54) Title: PYRAZINE COMPOUNDS FOR THE CONTROL OF INVERTEBRATE PESTS



(I)

(57) **Abstract:** The invention relates to compounds of formula (I) wherein the variables have the meanings as defined in the specification, to compositions comprising them, to active compound combinations comprising them, and to their use for protecting growing plants and animals from attack or infestation by invertebrate pests, furthermore, to seed comprising such compounds.




WO 2023/025617 A1

## Pyrazine compounds for the control of invertebrate pests

## Description

5 The invention relates to compounds of formula I



wherein

- 10  $R^1$  is H, OH,  $C_1$ - $C_6$ -alkyl,  $C_1$ - $C_6$ -haloalkyl,  $C_3$ - $C_6$ -cycloalkyl,  $C_3$ - $C_6$ -halocycloalkyl,  $C_1$ - $C_5$ -alkoxy,  $C_2$ - $C_4$ -alkenyl,  $C_2$ - $C_4$ -alkynyl,  $C_1$ - $C_4$ -alkyl- $C_3$ - $C_6$ -cycloalkyl,  $C_1$ - $C_4$ -alkyl- $C_3$ - $C_6$ -halocycloalkyl, which groups are unsubstituted, or partially or fully substituted with  $R^{11}$ ; or  $C(=N-R^{11})R^{12}$ ,  $C(O)R^{11a}$ ;
- 15  $R^{11}$  is CN,  $NO_2$ ,  $NR^{12}R^{13}$ ,  $C(O)NH_2$ ,  $C(S)NH_2$ ,  $C(O)OH$ ,  $OR^{14}$ ,  $Si(CH_3)_3$ ;  $C_1$ - $C_6$ -alkyl;  $C_1$ - $C_6$ -haloalkyl;  $C_2$ - $C_6$ -alkenyl;  $C_2$ - $C_6$ -haloalkenyl;  $C_2$ - $C_6$ -alkynyl;  $C_2$ - $C_6$ -haloalkynyl;  $C_3$ - $C_4$ -cycloalkyl- $C_1$ - $C_2$ -alkyl, which ring is unsubstituted or substituted with 1 or 2 halogen; 3- to 6-membered heterocyclyl, which rings are unsubstituted or substituted with  $R^a$ ; 5- or 6-membered hetaryl, or phenyl, which rings are unsubstituted or substituted with  $R^{3a}$ ;
- 20  $R^a$  halogen, CN,  $NO_2$ , OH,  $C_1$ - $C_4$ -alkyl,  $C_1$ - $C_4$ -haloalkyl,  $C_1$ - $C_4$ -alkoxy- $C_1$ - $C_4$ -alkyl,  $C_1$ - $C_4$ -alkoxy,  $C_1$ - $C_4$ -haloalkoxy,  $C_3$ - $C_4$ -cycloalkyl,  $C_3$ - $C_4$ -halocycloalkyl,  $S(O)_m$ - $C_1$ - $C_4$ -alkyl,  $S(O)_m$ - $C_1$ - $C_4$ -haloalkyl,  $S(O)_m$ - $C_3$ - $C_4$ -cycloalkyl,  $S(O)_m$ - $C_3$ - $C_4$ -halocycloalkyl, and oxo;
- 25  $R^{11a}$  is  $NR^{12}R^{13}$ ,  $C(O)NH_2$ ,  $C(S)NH_2$ ,  $C(O)OH$ ,  $OR^{14}$ ,  $Si(CH_3)_3$ ;  $C_1$ - $C_6$ -haloalkyl;  $C_2$ - $C_6$ -alkenyl;  $C_2$ - $C_6$ -haloalkenyl;  $C_2$ - $C_6$ -alkynyl;  $C_2$ - $C_6$ -haloalkynyl;  $C_3$ - $C_4$ -cycloalkyl- $C_1$ - $C_2$ -alkyl, which ring is unsubstituted or substituted with 1 or 2 halogen; 3- to 6-membered heterocyclyl, which rings are unsubstituted or substituted with  $R^a$ ;
- 30  $R^{12}$ ,  $R^{13}$  are independently from each other H,  $C_1$ - $C_4$ -alkyl,  $C_1$ - $C_4$ -alkoxy,  $C_1$ - $C_4$ -haloalkoxy,  $C_1$ - $C_4$ -haloalkyl,  $C_3$ - $C_6$ -cycloalkyl,  $C(O)$ - $C_1$ - $C_4$ -alkyl,  $C(O)$ - $C_1$ - $C_4$ -haloalkyl,  $C(O)$ - $C_3$ - $C_4$ -cycloalkyl,  $C(O)$ - $C_3$ - $C_4$ -halocycloalkyl,  $C(O)NR^{12}R^{13}$ ,  $S(O)_m$ - $C_1$ - $C_4$ -haloalkyl,  $S(O)_m$ - $C_3$ - $C_4$ -cycloalkyl,  $S(O)_m$ - $C_3$ - $C_4$ -halocycloalkyl; 3- to 6-membered heterocyclyl, which rings are unsubstituted or substituted with  $R^a$ ; 5- or 6-membered hetaryl, or phenyl, which rings are unsubstituted or substituted with  $R^{3a}$ ; or
- $R^{12}$  and  $R^{13}$ , together with the nitrogen atom to which they are bound, form a 3-, 4-, 5-, 6-

or 7-membered saturated, partially unsaturated or fully unsaturated heterocycle, which hetero-cycle may additionally contain 1 or 2 heteroatoms or heteroatom groups selected from N, O, and S(O)<sub>m</sub> as ring members, and which heterocycle is unsubstituted or substituted with one or more substituents selected from R<sup>a</sup>;

5 R<sup>121</sup> and R<sup>131</sup> are independently from each other H, C<sub>1</sub>-C<sub>4</sub>-alkyl, C<sub>1</sub>-C<sub>4</sub>-haloalkyl, C<sub>3</sub>-C<sub>6</sub>-cycloalkyl, C<sub>3</sub>-C<sub>6</sub>-halocycloalkyl, C<sub>1</sub>-C<sub>4</sub>-alkoxy, C<sub>1</sub>-C<sub>4</sub>-haloalkoxy; C<sub>1</sub>-C<sub>4</sub>-alkyl-phenyl, C<sub>1</sub>-C<sub>4</sub>-alkyl-3-6-membered hetaryl, phenyl, 3- to 6-membered heterocyclyl, which rings are unsubstituted or substituted with R<sup>a</sup>; or 5- or 6-membered hetaryl which rings are unsubstituted or substituted with R<sup>3a</sup>; or

10 R<sup>121</sup> and R<sup>131</sup> together with the nitrogen atom they are bound to form a 3-6 membered saturated, partially or fully unsaturated heterocycle, which may further contain 1 or 2 heteroatoms ring members selected from N, O and S, wherein S may be oxidized, which heterocycle is unsubstituted or substituted with R<sup>a</sup>;  
m is 0, 1, or 2;

15 R<sup>14</sup> is H, C<sub>1</sub>-C<sub>4</sub>-alkyl, C<sub>1</sub>-C<sub>4</sub>-haloalkyl, C<sub>3</sub>-C<sub>6</sub>-cycloalkyl, C<sub>3</sub>-C<sub>6</sub>-halocycloalkyl, C<sub>3</sub>-C<sub>4</sub>-cycloalkyl-C<sub>1</sub>-C<sub>2</sub>-alkyl, C<sub>3</sub>-C<sub>4</sub>-halocycloalkyl-C<sub>1</sub>-C<sub>2</sub>-alkyl, C(O)-C<sub>1</sub>-C<sub>4</sub>-alkyl, C(O)-C<sub>1</sub>-C<sub>4</sub>-haloalkyl, C(O)-C<sub>3</sub>-C<sub>4</sub>-cycloalkyl, C(O)-C<sub>3</sub>-C<sub>4</sub>-halocycloalkyl, or phenyl which is unsubstituted or partially or fully substituted with R<sup>3a</sup>;

R<sup>2</sup> is H, CN, C<sub>1</sub>-C<sub>3</sub>-alkyl, C<sub>1</sub>-C<sub>3</sub>-haloalkyl, C<sub>2</sub>-C<sub>3</sub>-alkenyl, C<sub>2</sub>-C<sub>3</sub>-alkynyl;

20 X is CH, CR<sup>3</sup>, or N;

R<sup>3</sup> is halogen, CN, NO<sub>2</sub>, C<sub>1</sub>-C<sub>4</sub>-alkyl, C<sub>3</sub>-C<sub>6</sub>-cycloalkyl, C<sub>1</sub>-C<sub>6</sub>-haloalkyl, C<sub>1</sub>-C<sub>6</sub>-halocycloalkyl, OR<sup>14</sup>, S(O)<sub>m</sub>-R<sup>14</sup>; which are unsubstituted or substituted with R<sup>3a</sup>;

R<sup>3a</sup> halogen, CN, NO<sub>2</sub>, OH, C<sub>1</sub>-C<sub>4</sub>-alkyl, C<sub>1</sub>-C<sub>4</sub>-haloalkyl, C<sub>1</sub>-C<sub>4</sub>-alkoxy-C<sub>1</sub>-C<sub>4</sub>-alkyl, C<sub>1</sub>-C<sub>4</sub>-alkoxy, C<sub>1</sub>-C<sub>4</sub>-haloalkoxy, C<sub>3</sub>-C<sub>4</sub>-cycloalkyl, C<sub>3</sub>-C<sub>4</sub>-halocycloalkyl, S(O)<sub>m</sub>-C<sub>1</sub>-C<sub>4</sub>-alkyl, S(O)<sub>m</sub>-C<sub>1</sub>-C<sub>4</sub>-haloalkyl, S(O)<sub>m</sub>-C<sub>3</sub>-C<sub>4</sub>-cycloalkyl, S(O)<sub>m</sub>-C<sub>3</sub>-C<sub>4</sub>-halocycloalkyl;  
25 n is 0, 1, 2, or 3;

R<sup>4</sup> is OR<sup>14</sup>, CN, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>3</sub>-C<sub>6</sub>-cycloalkyl, C<sub>1</sub>-C<sub>6</sub>-haloalkyl, C<sub>1</sub>-C<sub>6</sub>-halocycloalkyl, C<sub>2</sub>-C<sub>4</sub>-alkenyl, C<sub>2</sub>-C<sub>4</sub>-haloalkenyl, C<sub>2</sub>-C<sub>4</sub>-alkynyl, each unsubstituted or partially or fully substituted with R<sup>41</sup>;

30 S(O)<sub>m</sub>-C<sub>1</sub>-C<sub>4</sub>-alkyl, S(O)<sub>m</sub>-C<sub>1</sub>-C<sub>4</sub>-haloalkyl, S(O)<sub>m</sub>-C<sub>3</sub>-C<sub>4</sub>-cycloalkyl, S(O)<sub>m</sub>-C<sub>3</sub>-C<sub>4</sub>-halocycloalkyl, NR<sup>12</sup>R<sup>13</sup>, C(O)NR<sup>12</sup>R<sup>13</sup>, C(O)OR<sup>14</sup>, 3- to 6-membered heterocyclyl, which rings are unsubstituted or substituted with R<sup>a</sup>; 5- or 6-membered hetaryl, or phenyl, which rings are unsubstituted or partially or fully substituted with R<sup>3</sup>;

35 R<sup>41</sup> is H, OR<sup>15</sup>, NR<sup>12</sup>R<sup>13</sup>, C<sub>1</sub>-C<sub>4</sub>-alkyl, C<sub>1</sub>-C<sub>4</sub>-haloalkyl, C<sub>3</sub>-C<sub>6</sub>-cycloalkyl, C(O)-C<sub>1</sub>-C<sub>4</sub>-alkyl, C(O)-C<sub>1</sub>-C<sub>4</sub>-haloalkyl, C(O)-C<sub>3</sub>-C<sub>4</sub>-cycloalkyl, C(O)-C<sub>3</sub>-C<sub>4</sub>-halocycloalkyl, C(O)NR<sup>12</sup>R<sup>13</sup>;

$S(O)_m$ -C<sub>1</sub>-C<sub>4</sub>-haloalkyl,  $S(O)_m$ -C<sub>3</sub>-C<sub>4</sub>-cycloalkyl,  $S(O)_m$ -C<sub>3</sub>-C<sub>4</sub>-halocycloalkyl; 3- to 6-membered heterocyclyl, 5- or 6-membered hetaryl, or phenyl;

which non-aromatic cyclic R<sup>41</sup> groups are unsubstituted or partially or fully substituted with R<sup>a</sup>;

5 which aromatic R<sup>41</sup> groups are unsubstituted or partially or fully substituted with R<sup>3a</sup>;

R<sup>15</sup> is H, C<sub>1</sub>-C<sub>4</sub>-alkyl, or C<sub>1</sub>-C<sub>4</sub>-haloalkyl, C<sub>3</sub>-C<sub>6</sub>-cycloalkyl, C<sub>1</sub>-C<sub>6</sub>-halocycloalkyl, which carbon chains are unsubstituted or partially or fully substituted with R<sup>11</sup>; or 3- to 6-membered heterocyclyl, which rings are unsubstituted or substituted with R<sup>a</sup>; 5- or 6-membered hetaryl, or phenyl, which rings are unsubstituted or partially or fully substituted with R<sup>3a</sup>;

10

and the N-oxides, stereoisomers and agriculturally or veterinarily acceptable salts thereof.

The invention also provides agricultural compositions comprising at least one compound of formula I, a stereoisomer thereof and/or an agriculturally acceptable salt thereof and at least one liquid and/or solid carrier, especially at least one inert liquid and/or solid agriculturally acceptable carrier.

15

The invention also provides a veterinary composition comprising at least one compound of formula I, a stereoisomer thereof and/or a veterinarily acceptable salt thereof and at least one liquid and/or solid carrier, especially at least one inert veterinarily liquid and/or solid acceptable carrier.

20

The invention also provides a method for controlling invertebrate pests which method comprises treating the pests, their food supply, their habitat or their breeding ground or a cultivated plant, plant propagation materials (such as seed), soil, area, material or environment in which the pests are growing or may grow, or the materials, cultivated plants, plant propagation materials (such as seed), soils, surfaces or spaces to be protected from pest attack or infestation with a pesticidally effective amount of a compound of formula I or a salt thereof as defined herein.

25

The invention also relates to plant propagation material, in particular seed, comprising at least one compound of formula I and/or an agriculturally acceptable salt thereof.

The invention further relates to a method for treating or protecting an animal from infestation or infection by parasites which comprises bringing the animal in contact with a parasiticidally effective amount of a compound of formula I or a veterinarily acceptable salt thereof. Bringing the animal in contact with the compound I, its salt or the veterinary composition of the invention means applying or administering it to the animal.

30


WO 2017/192385, WO2020/070049, WO2021/037614, WO2021/122645, WO2021/068179, and WO2021/069575 describe structurally closely related active compounds. These compounds are mentioned to be useful for combating invertebrate pests.

35

Nevertheless, there remains a need for highly effective and versatile agents for combating invertebrate pests. It is therefore an object of the invention to provide compounds having a good pesticidal activity and showing a broad activity spectrum against a large number of different invertebrate pests, especially against difficult to control pests, such as insects.

- 5 It has been found that these objects can be achieved by compounds of formula I as depicted and defined below, and by their stereoisomers, salts, tautomers and N-oxides, in particular their agriculturally acceptable salts.


Compounds I can be obtained by alkylation of a compound II with a suitable alkylating agent III (e.g. alkyl halide). In formula III R<sup>1</sup> has the meaning as in formula I, and Y is a nucleophilic leaving group, such as a halide, preferably Br or Cl. The alkylation can be effected under standard conditions known from literature.



This transformation is usually carried out at temperatures of from -10°C to +110°C, preferably from 0°C to 25°C, in an inert solvent and in the presence of a base [cf. WO 2002100846].

The starting materials are generally reacted with one another in equimolar amounts. In terms of yield, it may be advantageous to employ an excess of III, based on II.

Compounds II can be obtained by reaction of an amino compound IV with a carboxylic acid V



This transformation is usually carried out at temperatures of from -20°C to 50°C, preferably from 0°C to 25°C, in an inert solvent, in the presence of a base [cf. A. El-Faham, Chem. Rev. 2011, 6557], or alternatively in two steps by preparation of an intermediate acyl chloride from V under conditions known from literature, e.g. by reaction with thionyl chloride or oxalyl chloride in dimethylformamide (cf. Schaefer et al, Organic Syntheses 1929, 32) followed by reaction with IV in the presence of a base, optionally under Schotten–Baumann conditions (Baumann, Chem. Ber. 1886, 3218). Suitable peptide coupling reagents are, for example, dicyclohexylcarbodiimide, diisopropylcarbodiimide, 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide hydrochloride, or

chloro-N,N,N',N'-tetramethylformamidinium hexafluorophosphate, which are commonly used together with catalytic, stoichiometric, excess amounts of additives, such as 1-hydroxybenzotriazole, 1-hydroxy-7-aza-benzotriazole, 4-(dimethylamino)pyridine, and/or 1-methylimidazole.

5 Suitable solvents are halogenated hydrocarbons, such as dichloromethane (DCM) or 1,2-dichloroethane, ethers, such as diethylether, tetrahydrofuran (THF) or 1,4-dioxane, or high-boiling solvents such as dimethylformamide (DMF), preferably DCM or DMF, or in aqueous media.

Suitable bases are, in general, inorganic compounds, such as alkali metal and alkaline earth metal hydroxides, such as LiOH, NaOH, KOH, or Ca(OH)<sub>2</sub>, alkali metal and alkaline earth metal carbonates, such as Na<sub>2</sub>CO<sub>3</sub>, K<sub>2</sub>CO<sub>3</sub>, or Cs<sub>2</sub>CO<sub>3</sub>, alkali metal bicarbonates, such as NaHCO<sub>3</sub>, or organic bases, e.g. tertiary amines, such as triethylamine, diisopropylethylamine, N-methylpiperidine, or basic aromatic rings, such as pyridine, 2,4,6-collidine, 2,6-lutidine, or 4-(dimethylamino)pyridine, or bicyclic amines, such as 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), 1,5-diazabicyclo[4.3.0]non-5-ene (DBN), or 1,4-diazabicyclo[2.2.2]octane (DABCO).


15 Particular preference is given to triethylamine, diisopropylethylamine, and NaOH.

The bases are generally employed in stoichiometric or excess amounts; however, they can also be used in catalytic amounts or, if appropriate, as the solvent.

The starting materials are generally reacted with one another in equimolar amounts. In terms of yield, it may be advantageous to employ an excess of IV based on V.

20


Compounds IV can be obtained by reductive amination of a compound VI.



This transformation is usually carried out at temperatures of from 0°C to 130°C, preferably from 20°C to 70°C, generally in alcoholic and/or aqueous media and in the presence of a reagent and a reducing agent [cf. WO2021037614]. Suitable solvents are alcohols, such as methanol, ethanol, n-propanol, 2-propanol, or n-butanol, or water, preferably methanol. It is also possible to use mixtures of the aforementioned solvents. Suitable reagents are ammonium acetate (NH<sub>4</sub>Ac), ammonium formate, NH<sub>4</sub>OH, NH<sub>4</sub>Cl, or ammonia. Suitable reducing agents are NaBH<sub>3</sub>CN, sodium triacetoxyborohydride, or NaBH<sub>4</sub>.

30 Preference is given to ammonium acetate and NaBH<sub>3</sub>CN, resp.

Compounds VI are obtainable from compounds VII in a two-step sequence consisting of Stille coupling of VII with an alkoxyalkenylstannane such as VIII followed by hydrolysis of the resulting enol ether moiety to the ketone VI.




5 The Stille coupling reaction is usually carried out at temperatures from 50°C to 150°C, preferably from 70°C to 120°C, in an inert solvent in the presence of one or more catalysts and optionally in the presence of one or more additives and a base [cf. H. Lin et al., *Bioorg Med Chem Lett* 2010, 679]. Suitable solvents are aromatic hydrocarbons such as toluene, o-, m-, p-xylene, and mesitylene, or ethers such as THF and 1,4-dioxane, preferably toluene or 1,4-dioxane. It is also  
10 possible to use mixtures of the aforementioned solvents.

Suitable catalysts are palladium complexes, such as tetrakis(triphenylphosphine)palladium, tris(dibenzylideneacetone)dipalladium, palladium diacetate, dichloro-bis(triphenylphosphine)palladium, and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium, preferably dichlorobis(triphenylphosphine)palladium. Further suitable optional catalysts are common ligands, such as  
15 dicyclohexyl[2',4',6'-tris(propan-2-yl)[1,1'-biphenyl]-2-yl]phosphine or tri-phenylphosphine. Suitable additives are, in general, inorganic compounds, such as cesium fluoride and cuprous iodide. The starting materials are generally reacted with one another in equimolar amounts. In terms of yield, it may be advantageous to employ an excess of VIII, based on VII.

The hydrolysis is usually carried out at temperatures from -20°C to 40°C, preferably from 0°C  
20 to 25°C, in aqueous acidic media containing aqueous HCl at concentrations between 0.5M and 3M and optionally containing an organic solvent such as acetonitrile, acetone, THF, or methanol (cf H. Lin et al., *Bioorg Med Chem Lett* 2010, 679).

Compounds VII are obtainable from triazoles IX. In formula X, group Z is a leaving group, e.g. a halide, such as I, Br, and Cl, or a sulfonate, such as triflate or mesylate.



25


This transformation is usually carried out at temperatures from 0°C to 100°C, preferably from 10°C to 60°C, in an inert solvent and in the presence of a base [cf. J. Bradshaw et al., *J. Heterocycl. Chem.* 1986, 361]. Suitable solvents are halogenated hydrocarbons, such as DCM, 1,2-

dichloroethane, or chloroform, ethers, such as diethylether, tert-butylmethylether, dioxane, or THF, nitriles, such as acetonitrile or propionitrile, alcohols, such as methanol or ethanol, and polar aprotic solvents, such as dimethyl sulfoxide (DMSO), DMF, or dimethylacetamide (DMA), preferably acetonitrile. It is also possible to use mixtures of the aforementioned solvents.

5 Suitable bases are, in general, inorganic compounds, such as alkali metal and alkaline earth metal hydrides, such as NaH, KH, alkali metal and alkaline earth metal carbonates, such as Na<sub>2</sub>CO<sub>3</sub>, K<sub>2</sub>CO<sub>3</sub>, or Cs<sub>2</sub>CO<sub>3</sub>, alkali metal bicarbonates, such as NaHCO<sub>3</sub>, or organic bases, e.g. tertiary amines such as triethylamine or diisopropylethylamine. Preference is given to K<sub>2</sub>CO<sub>3</sub>. The bases are generally employed in equimolar amounts; however, they can also be used in  
10 excess or, if appropriate, as solvent.


The starting materials are generally reacted with one another in equimolar amounts. In terms of yield, it may be advantageous to employ an excess of X, based on IX.

15 Triazole IX is obtainable from compound XI by reaction with 1 to 1.5 equivalents of hydrazine hydrate XII in acetic acid (AcOH) as solvent, optionally using an alcohol, such as methanol, ethanol, or 2-propanol, or an ether, such as 1,4-dioxane, as a cosolvent, at temperatures from 25°C to 110°C, as known from literature (cf. Lin et al, J. Org. Chem. 1979, 4160; Wroblewski et al, J. Med. Chem. 2019, 8973). Alternatively, compounds VII can be directly obtained from compound XI by reaction with a substituted hydrazine of the type R<sup>4</sup>NH-NH<sub>2</sub>.



20


Compound XI is obtainable from commercially available 3-chloropyrazine-2-carboxamide (XII) by reaction with N,N-dimethylformamide dimethyl acetal (DMFDMA).



25 This transformation is usually carried out using 1.5 to 3 equivalents of DMFDMA at temperatures from 0°C to 100°C, preferably from 25°C to 90°C, in an inert solvent [cf. Lin et al, J. Org. Chem. 1979, 4160; Wroblewski et al, J. Med. Chem. 2019, 8973]. Suitable solvents are halogenated hydrocarbons, such as DCM and 1,2-dichloroethane, ethers, such as THF, aromatic solvents, such as toluene, and polar aprotic solvents, such as DMSO, preferably DCM.

30 The starting materials are generally reacted with one another in equimolar amounts. In terms of yield, it may be advantageous to employ an excess of DMFDMA, based on XII.

Further, compounds I can be obtained from 4-methoxybenzyl- (PMB)-substituted compounds I (R<sup>4</sup>=PMB), or a regioisomer of such compounds I in which the PMB group is attached to any one of the three nitrogen atoms of the triazole ring, in a two-step sequence involving removal of the PMB group by treatment with an acid such as TFA, e.g. as described in WO2011076725, followed by reaction of the intermediate (Int) using the reagents and reaction conditions as described above for the synthesis of compounds VII from compounds IX. Intermediate compounds (Int) are novel. The variables in formula (Int) are as defined for formula I.



The reaction mixtures are worked up in a customary manner, e.g. by mixing with water, extracting with an appropriate organic solvent, separating the phases and, if appropriate, chromatographic purification of the crude products. Some of the intermediates and end products are obtained in the form of colourless or slightly brownish viscous oils which are purified or freed from volatile components under reduced pressure and at moderately elevated temperature. If the intermediates and end products are obtained as solids, purification can also be carried out by recrystallization or digestion.

If individual compounds I cannot be obtained by the routes described above, they can be prepared by derivatization of other compounds I.

However, if the synthesis yields mixtures of isomers, a separation is generally not necessarily required since in some cases the individual isomers can be interconverted during work-up for use or during application (e.g. under the action of light, acids or bases). Such conversions may also take place after use, e.g. in the treatment of plants in the treated plant, or in the pest to be controlled.

The organic moieties groups mentioned in the above definitions of the variables are - like the term halogen - collective terms for individual listings of the individual group members. The prefix C<sub>n</sub>-C<sub>m</sub> indicates in each case the possible number of carbon atoms in the group.

The term "partially or fully substituted" by a radical means that in general the group is substituted with same or different radicals.

The term "halogen" denotes in each case fluorine, bromine, chlorine, or iodine, in particular fluorine, chlorine, or bromine.

The term "alkyl" as used herein and in the alkyl moieties of alkylamino, alkylcarbonyl, alkylthio, alkylsulfinyl, alkylsulfonyl and alkoxyalkyl denotes in each case a straight-chain or branched

alkyl group having usually from 1 to 10 carbon atoms, frequently from 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms, more preferably from 1 to 3 carbon atoms. Examples of an alkyl group are methyl (Me), ethyl (Et), n-propyl (n-Pr), iso-propyl, n-butyl, 2-butyl, iso-butyl, tert-butyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl, 2-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-1-methylpropyl, and 1-ethyl-2-methylpropyl.

The term "haloalkyl" as used herein and in the haloalkyl moieties of haloalkylcarbonyl, haloalkoxycarbonyl, haloalkylthio, haloalkylsulfonyl, haloalkylsulfinyl, haloalkoxy and haloalkoxyalkyl, denotes in each case a straight-chain or branched alkyl group having usually from 1 to 10 carbon atoms, frequently from 1 to 6 carbon atoms, preferably from 1 to 4 carbon atoms, wherein the hydrogen atoms of this group are partially or totally replaced with halogen atoms. Preferred haloalkyl moieties are selected from C<sub>1</sub>-C<sub>4</sub>-haloalkyl, more preferably from C<sub>1</sub>-C<sub>3</sub>-haloalkyl or C<sub>1</sub>-C<sub>2</sub>-haloalkyl, in particular from C<sub>1</sub>-C<sub>2</sub>-fluoroalkyl such as fluoromethyl, difluoromethyl, trifluoromethyl, 1-fluoroethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, pentafluoroethyl, and the like.

The term "alkoxy" as used herein denotes in each case a straight-chain or branched alkyl group which is bonded via an oxygen atom and has usually from 1 to 10 carbon atoms, frequently from 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms. Examples of an alkoxy group are methoxy, ethoxy, n-propoxy, iso-propoxy, n-butyloxy, 2-butyloxy, iso-butyloxy, tert.-butyloxy, and the like.

The term "alkoxyalkyl" as used herein refers to alkyl usually comprising 1 to 10, frequently 1 to 4, preferably 1 to 2 carbon atoms, wherein 1 carbon atom carries an alkoxy radical usually comprising 1 to 4, preferably 1 or 2 carbon atoms as defined above. Examples are CH<sub>2</sub>OCH<sub>3</sub>, CH<sub>2</sub>-OC<sub>2</sub>H<sub>5</sub>, 2-(methoxy)ethyl, and 2-(ethoxy)ethyl.

The term "haloalkoxy" as used herein denotes in each case a straight-chain or branched alkoxy group having from 1 to 10 carbon atoms, frequently from 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms, wherein the hydrogen atoms of this group are partially or totally replaced with halogen atoms, in particular fluorine atoms. Preferred haloalkoxy moieties include C<sub>1</sub>-C<sub>4</sub>-haloalkoxy, in particular C<sub>1</sub>-C<sub>2</sub>-fluoroalkoxy, such as fluoromethoxy, difluoromethoxy, trifluoromethoxy, 1-fluoroethoxy, 2-fluoroethoxy, 2,2-difluoroethoxy, 2,2,2-trifluoroethoxy, 2-chloro-2-fluoroethoxy, 2-chloro-2,2-difluoro-ethoxy, 2,2-dichloro-2-fluoroethoxy, 2,2,2-trichloroethoxy, pentafluoroethoxy and the like.

The term "alkylthio" (alkylsulfanyl: S-alkyl) as used herein refers to a straight-chain or branched saturated alkyl group having 1 to 10 carbon atoms, preferably 1 to 4 carbon atoms (= C<sub>1</sub>-C<sub>4</sub>-alkylthio), more preferably 1 to 3 carbon atoms, which is attached via a sulfur atom.

The term "haloalkylthio" as used herein refers to an alkylthio group as mentioned above wherein the hydrogen atoms are partially or fully substituted by fluorine, chlorine, bromine and/or iodine.

5 The term "alkylsulfinyl" (alkylsulfoxyl: S(=O)-alkyl), as used herein refers to a straight-chain or branched saturated alkyl group (as mentioned above) having 1 to 10 carbon atoms, preferably 1 to 4 carbon atoms (= C<sub>1</sub>-C<sub>4</sub>-alkylsulfinyl), more preferably 1 to 3 carbon atoms bonded through the sulfur atom of the sulfinyl group at any position in the alkyl group.

10 The term "haloalkylsulfinyl" as used herein refers to an alkylsulfinyl group as mentioned above wherein the hydrogen atoms are partially or fully substituted by fluorine, chlorine, bromine and/or iodine.

The term "alkylsulfonyl" (S(=O)<sub>2</sub>-alkyl) as used herein refers to a straight-chain or branched saturated alkyl group having 1 to 10 carbon atoms, preferably 1 to 4 carbon atoms (= C<sub>1</sub>-C<sub>4</sub>-alkylsulfonyl), preferably 1 to 3 carbon atoms, which is bonded via the sulfur atom of the sulfonyl group at any position in the alkyl group.

15 The term "haloalkylsulfonyl" as used herein refers to an alkylsulfonyl group as mentioned above wherein the hydrogen atoms are partially or fully substituted by fluorine, chlorine, bromine and/or iodine.

The term "alkylcarbonyl" refers to an alkyl group as defined above, which is bonded via the carbon atom of a carbonyl group (C=O) to the remainder of the molecule.

20 The term "haloalkylcarbonyl" refers to an alkylcarbonyl group as mentioned above, wherein the hydrogen atoms are partially or fully substituted by fluorine, chlorine, bromine and/or iodine.

The term "alkoxycarbonyl" refers to an alkylcarbonyl group as defined above, which is bonded via an oxygen atom to the remainder of the molecule.

25 The term "haloalkoxycarbonyl" refers to an alkoxycarbonyl group as mentioned above, wherein the hydrogen atoms are partially or fully substituted by fluorine, chlorine, bromine and/or iodine.

30 The term "alkenyl" as used herein denotes in each case a singly unsaturated hydrocarbon radical having usually 2 to 10, frequently 2 to 6, preferably 2 to 4 carbon atoms, e.g. vinyl, allyl (2-propen-1-yl), 1-propen-1-yl, 2-propen-2-yl, methallyl (2-methylprop-2-en-1-yl), 2-buten-1-yl, 3-buten-1-yl, 2-penten-1-yl, 3-penten-1-yl, 4-penten-1-yl, 1-methylbut-2-en-1-yl, 2-ethylprop-2-en-1-yl and the like.

The term "haloalkenyl" as used herein refers to an alkenyl group as defined above, wherein the hydrogen atoms are partially or totally replaced with halogen atoms.

35 The term "alkynyl" as used herein denotes in each case a singly unsaturated hydrocarbon radical having usually 2 to 10, frequently 2 to 6, preferably 2 to 4 carbon atoms, e.g. ethynyl, propargyl (2-propyn-1-yl), 1-propyn-1-yl, 1-methylprop-2-yn-1-yl, 2-butyne-1-yl, 3-butyne-1-yl, 1-

pentyn-1-yl, 3-pentyn-1-yl, 4-pentyn-1-yl, 1-methylbut-2-yn-1-yl, 1-ethylprop-2-yn-1-yl and the like.

The term "haloalkynyl" as used herein refers to an alkynyl group as defined above, wherein the hydrogen atoms are partially or totally replaced with halogen atoms.

5 The term "cycloalkyl" as used herein and in the cycloalkyl moieties of cycloalkoxy and cycloalkylthio denotes in each case a monocyclic cycloaliphatic radical having usually from 3 to 10 or from 3 to 6 carbon atoms, such as cyclopropyl (C<sub>3</sub>H<sub>5</sub>), cyclobutyl (C<sub>4</sub>H<sub>7</sub>), cyclopentyl (C<sub>5</sub>H<sub>9</sub>), cyclohexyl (C<sub>6</sub>H<sub>11</sub>), cycloheptyl, cyclooctyl, cyclononyl and cyclodecyl or cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

10 The term "halocycloalkyl" as used herein and in the halocycloalkyl moieties of halocycloalkoxy and halocycloalkylthio denotes in each case a monocyclic cycloaliphatic radical having usually from 3 to 10 C atoms or 3 to 6 C atoms, wherein at least one, e.g. 1, 2, 3, 4 or 5 of the hydrogen atoms, are replaced by halogen, in particular by fluorine or chlorine. Examples are 1- and 2-fluorocyclopropyl, 1,2-, 2,2- and 2,3-difluorocyclopropyl, 1,2,2-trifluorocyclopropyl, 2,2,3,3-tetrafluorocyclopropyl, 1- and 2-chlorocyclopropyl, 1,2-, 2,2- and 2,3-dichlorocyclopropyl, 1,2,2-trichlorocyclopropyl, 1,2,2,3-tetrachlorocyclopropyl, 1-, 2- and 3-fluorocyclopentyl, 1,2-, 2,2-, 2,3-, 3,3-, 3,4-, 2,5-difluorocyclopentyl, 1-, 2- and 3-chlorocyclopentyl, 1,2-, 2,2-, 2,3-, 3,3-, 3,4-, 2,5-dichlorocyclopentyl and the like.

20 The term "cycloalkenyl" as used herein and in the cycloalkenyl moieties of cycloalkenyloxy and cycloalkenylthio denotes in each case a mono- or bicyclic, preferably monocyclic, singly unsaturated non-aromatic radical having usually from 3 to 10, e.g. 3 or 4 or from 5 to 10 carbon atoms, preferably from 3- to 8 carbon atoms. Examples are cyclopenten-1-yl, and cyclohexen-1-yl.

25 The term "halocycloalkenyl" as used herein and in the halocycloalkenyl moieties of halocycloalkenyloxy and halocycloalkenylthio denotes in each case a monocyclic singly unsaturated non-aromatic radical having usually from 3 to 10, e.g. 3 or 4 or from 5 to 10 carbon atoms, preferably from 3- to 8 carbon atoms, wherein at least one, e.g. 1, 2, 3, 4 or 5 of the hydrogen atoms, are replaced by halogen, in particular by fluorine or chlorine. Examples are 3,3-difluorocyclopropen-1-yl and 3,3-dichlorocyclopropen-1-yl.

30 The term "cycloalkenylalkyl" refers to a cycloalkenyl group as defined above which is bonded via an alkyl group, such as a C<sub>1</sub>-C<sub>5</sub>-alkyl group or a C<sub>1</sub>-C<sub>4</sub>-alkyl group, in particular a methyl group (= cycloalkenylmethyl), to the remainder of the molecule.

35 The term "carbocycle" or "carbocyclyl" includes in general a 3- to 12-membered, preferably a 3- to 8-membered or a 5- to 8-membered, more preferably a 5- or 6-membered mono-cyclic, non-aromatic ring comprising 3 to 12, preferably 3 to 8 or 5 to 8, more preferably 5 or 6 carbon atoms. Preferably, the term "carbocycle" covers cycloalkyl and cycloalkenyl groups as defined above.

The term "heterocycle" or "heterocyclyl" includes in general 3- to 12-membered, preferably 3- to 6-membered, in particular 6-membered monocyclic heterocyclic non-aromatic radicals. The heterocyclic non-aromatic radicals usually comprise 1, 2, 3, 4 or 5, preferably 1, 2 or 3 heteroatoms selected from N, O, and S as ring members, wherein S-atoms as ring members may be present as S, SO, or SO<sub>2</sub>. Examples of 5- or 6-membered heterocyclic radicals comprise saturated or unsaturated, non-aromatic heterocyclic rings, such as oxiranyl, oxetanyl, thietanyl, thietanyl-S-oxid (S-oxothietanyl), thietanyl-S-dioxid (S-dioxothiethanyl), pyrrolidinyl, pyrrolinyl, pyrazolinyl, tetrahydrofuranyl, dihydrofuranyl, 1,3-dioxolanyl, thiolanyl, S-oxothiolanyl, S-dioxothiolanyl, dihydrothienyl, S-oxodihydrothienyl, S-dioxodihydrothienyl, oxazolidinyl, oxazolinyl, thiazolinyl, oxathiolanyl, piperidinyl, piperazinyl, pyranyl, dihydropyranyl, tetrahydropyranyl, 1,3- and 1,4-dioxanyl, thiopyranyl, S.oxothiopyranyl, S-dioxothiopyranyl, dihydrothiopyranyl, S-oxodihydrothiopyranyl, S-dioxodihydrothiopyranyl, tetrahydrothiopyranyl, S-oxotetrahydrothiopyranyl, S-dioxotetrahydrothiopyranyl, morpholinyl, thiomorpholinyl, S-oxothiomorpholinyl, S-dioxothiomorpholinyl, thiazinyl and the like. Examples for heterocyclic ring also comprising 1 or 2 carbonyl groups as ring members comprise pyrrolidin-2-onyl, pyrrolidin-2,5-dionyl, imidazolidin-2-onyl, oxazolidin-2-onyl, thiazolidin-2-only, and the like.

The term "hetaryl" includes monocyclic 5- or 6-membered heteroaromatic radicals comprising as ring members 1, 2, 3 or 4 heteroatoms selected from N, O, and S. Examples of 5- or 6-membered heteroaromatic radicals include pyridyl, i.e. 2-, 3-, or 4-pyridyl, pyrimidinyl, i.e. 2-, 4- or 5-pyrimidinyl, pyrazinyl, pyridazinyl, i.e. 3- or 4-pyridazinyl, thienyl, i.e. 2- or 3-thienyl, furyl, i.e. 2- or 3-furyl, pyrrolyl, i.e. 2- or 3-pyrrolyl, oxazolyl, i.e. 2-, 3- or 5-oxazolyl, isoxazolyl, i.e. 3-, 4- or 5-isoxazolyl, thiazolyl, i.e. 2-, 3- or 5-thiazolyl, isothiazolyl, i.e. 3-, 4- or 5-isothiazolyl, pyrazolyl, i.e. 1-, 3-, 4- or 5-pyrazolyl, i.e. 1-, 2-, 4- or 5-imidazolyl, oxadiazolyl, e.g. 2- or 5-[1,3,4]oxadiazolyl, 4- or 5-(1,2,3-oxadiazol)yl, 3- or 5-(1,2,4-oxadiazol)yl, 2- or 5-(1,3,4-thiadiazol)yl, thiadiazolyl, e.g. 2- or 5-(1,3,4-thiadiazol)yl, 4- or 5-(1,2,3-thiadiazol)yl, 3- or 5-(1,2,4-thiadiazol)yl, triazolyl, e.g. 1H-, 2H- or 3H-1,2,3-triazol-4-yl, 2H-triazol-3-yl, 1H-, 2H-, or 4H-1,2,4-triazolyl and tetrazolyl, i.e. 1H- or 2H-tetrazolyl. The term "hetaryl" also includes bicyclic 8 to 10-membered heteroaromatic radicals comprising as ring members 1, 2 or 3 heteroatoms selected from N, O, and S, wherein a 5- or 6-membered heteroaromatic ring is fused to a phenyl ring or to a 5- or 6-membered heteroaromatic radical. Examples of a 5- or 6-membered heteroaromatic ring fused to a phenyl ring or to a 5- or 6-membered heteroaromatic radical include benzofuranyl, benzothienyl, indolyl, indazolyl, benzimidazolyl, benzoxathiazolyl, benzoxadiazolyl, benzothiadiazolyl, benzoxazinyl, chinolinyl, isochinolinyl, purinyl, 1,8-naphthyridyl, pteridyl, pyrido[3,2-d]pyrimidyl or pyridoimidazolyl and the like. These fused hetaryl radicals may be bonded to the remainder of the molecule via any ring atom of 5- or 6-membered heteroaromatic ring or via a carbon atom of the fused phenyl moiety.

The terms "heterocyclylalkyl" and "hetarylalkyl" refer to heterocyclyl or hetaryl, respectively, as defined above which are bonded via a C<sub>1</sub>-C<sub>5</sub>-alkyl group or a C<sub>1</sub>-C<sub>4</sub>-alkyl group, in particular a methyl group (= heterocyclylmethyl or hetarylmethyl, respectively), to the remainder of the molecule.

- 5 The term "arylalkyl" and "phenylalkyl" refer to aryl as defined above and phenyl, respectively, which are bonded via C<sub>1</sub>-C<sub>5</sub>-alkyl group or a C<sub>1</sub>-C<sub>4</sub>-alkyl group, in particular a methyl group (= arylmethyl or phenylmethyl), to the remainder of the molecule, examples including benzyl, 1-phenylethyl, 2-phenylethyl, 2-phenoxyethyl etc.


- 10 The terms "alkylene", "cycloalkylene", "heterocycloalkylene", "alkenylene", "cycloalkenylene", "heterocycloalkenylene" and "alkynylene" refer to alkyl, cycloalkyl, heterocycloalkyl, alkenyl, cycloalkenyl, heterocycloalkenyl and alkynyl as defined above, respectively, which are bonded to the remainder of the molecule, via two atoms, preferably via two carbon atoms, of the respective group, so that they represent a linker between two moieties of the molecule.

- 15 In a particular embodiment, the variables of the compounds of the formula I have the following meanings, these meanings, both on their own and in combination with one another, being particular embodiments of the compounds of the formula I.

- 20 Embodiments and preferred compounds of the invention for use in pesticidal methods and for insecticidal application purposes are outlined in the following paragraphs.

With respect to the variables, the particularly preferred embodiments of the intermediates correspond to those of the compounds of the formula I.

- 25 In a preferred embodiment, the compounds I are present in form of a mixture of compounds I.A and I.B, wherein compound I.A with S-configuration of the carbon atom neighboring the nitrogen is present in an amount of more than 50% by weight, in particular of at least 70% by weight, more particularly of at least 85% by weight, specifically of at least 90% by weight, based on the total weight of compounds I.A and I.B.




In one particularly preferred embodiment of the invention, the method comprises the step of contacting the plant, parts of it, its propagation material, the pests, their food supply, habitat or breeding grounds with a pesticidally effective amount of a compound of formula I.A.

- 5 Preferably  $R^1$  is H,  $C_1$ - $C_6$ -alkyl,  $C_3$ - $C_6$ -alkynyl,  $C_3$ - $C_6$ -cycloalkyl, or  $C_1$ - $C_4$ -alkyl- $C_3$ - $C_6$ -cycloalkyl.


Preferably  $R^2$  is  $CH_3$ .

X is preferably CH or  $CR^3$ , particularly CH. Such compounds correspond to Formula I.1



10

In another embodiment X is N. Such compounds correspond to formula I.2.



- 15  $R^3$  is preferably halogen, CN,  $C_1$ - $C_4$ -haloalkyl,  $C_1$ - $C_4$ -haloalkoxy,  $C_3$ - $C_4$ -cycloalkyl unsubstituted or substituted with one or more CN,  $C_3$ - $C_4$ -halocycloalkyl,  $S(O)_m$ - $C_1$ - $C_4$ -alkyl,  $S(O)_m$ - $C_1$ - $C_4$ -haloalkyl,  $S(O)_m$ - $C_3$ - $C_4$ -cycloalkyl,  $S(O)_m$ - $C_3$ - $C_4$ -halocycloalkyl. Index m in  $R^3$  is preferably 2. Index n is preferably 2.

- In another embodiment  $R^3$  is preferably halogen, CN,  $C_1$ - $C_4$ -haloalkyl,  $C_1$ - $C_4$ -haloalkoxy,  $C_3$ - $C_4$ -cycloalkyl unsubstituted or substituted with one or more  $R^{3a}$ , wherein  $R^{3a}$  is preferably CN, OH,  $C_1$ - $C_4$ -alkoxy. Index m in  $R^3$  is preferably 2. Index n is preferably 2.
- 20

$R^3$  groups stand preferably in positions 3 and 5.

- In another embodiment  $R^3$  is preferably halogen, CN,  $C_1$ - $C_4$ -haloalkyl,  $C_1$ - $C_4$ -haloalkoxy,  $C_3$ - $C_4$ -cycloalkyl,  $C_3$ - $C_4$ -halocycloalkyl,  $S(O)_m$ - $C_1$ - $C_4$ -alkyl,  $S(O)_m$ - $C_1$ - $C_4$ -haloalkyl,  $S(O)_m$ - $C_3$ - $C_4$ -cycloalkyl,  $S(O)_m$ - $C_3$ - $C_4$ -halocycloalkyl, or
- 25

$S(O)_m$ - $R^{14}$ , wherein  $R^{14}$  is phenyl, which is partially substituted with  $R^{3a}$ .

In another embodiment of formula I compounds  $R^3$  is halogen, CN,  $NO_2$ ,  $C_1$ - $C_4$ -alkyl,  $C_3$ - $C_6$ -cycloalkyl,  $C_1$ - $C_6$ -haloalkyl,  $C_1$ - $C_6$ -halocycloalkyl,  $OR^{14}$ ,  $S(O)_m-R^{14}$ ; wherein rings are unsubstituted or substituted with  $R^{11}$ .

- 5  $R^4$  is preferably  $C_1$ - $C_4$ -alkyl,  $C_1$ - $C_4$ -haloalkyl,  $C_1$ - $C_4$ -alkoxy- $C_1$ - $C_4$ -alkyl,  $CH_2C(O)NH$ - $C_1$ - $C_6$ -alkyl,  $S(O)_m$ - $C_1$ - $C_4$ -alkyl, or phenyl unsubstituted or substituted with one or more groups  $R^3$ .

In particular with a view to their use, preference is given to the compounds of formula I compiled in the tables below, which compounds correspond to formula I.1\* ,and I.2\* , resp.. Each of the groups mentioned for a substituent in the tables is furthermore per se, independently of the combination in which it is mentioned, a particularly preferred aspect of the substituent in question.




Table 1

- 15 Compounds of formula I.1\* in which  $R^4$  is CN, and the combination of  $R^1$  and  $(R^3)_n$  for a compound corresponds in each case to one row of Table A

Table 2

Compounds of formula I.1\* in which  $R^4$  is  $CH_3$ , and the combination of  $R^1$  and  $(R^3)_n$  for a compound corresponds in each case to one row of Table A

- 20 Table 3

Compounds of formula I.1\* in which  $R^4$  is  $C_2H_5$ , and the combination of  $R^1$  and  $(R^3)_n$  for a compound corresponds in each case to one row of Table A

Table 4

- 25 Compounds of formula I.1\* in which  $R^4$  is  $CH_2CH_2CH_3$ , and the combination of  $R^1$  and  $(R^3)_n$  for a compound corresponds in each case to one row of Table A

Table 5

Compounds of formula I.1\* in which  $R^4$  is  $CH(CH_3)_2$ , and the combination of  $R^1$  and  $(R^3)_n$  for a compound corresponds in each case to one row of Table A

Table 6

- 30 Compounds of formula I.1\* in which  $R^4$  is  $cC_3H_5$ , and the combination of  $R^1$  and  $(R^3)_n$  for a compound corresponds in each case to one row of Table A

## Table 7

Compounds of formula I.1\* in which R<sup>4</sup> is CH<sub>2</sub>CF<sub>3</sub>, and the combination of R<sup>1</sup> and (R<sup>3</sup>)<sub>n</sub> for a compound corresponds in each case to one row of Table A

## Table 8

- 5 Compounds of formula I.1\* in which R<sup>4</sup> is CH<sub>2</sub>OCH<sub>3</sub>, and the combination of R<sup>1</sup> and (R<sup>3</sup>)<sub>n</sub> for a compound corresponds in each case to one row of Table A

## Table 9

Compounds of formula I.1\* in which R<sup>4</sup> is C(=O)NH<sub>2</sub>, and the combination of R<sup>1</sup> and (R<sup>3</sup>)<sub>n</sub> for a compound corresponds in each case to one row of Table A

- 10 Table 10

Compounds of formula I.1\* in which R<sup>4</sup> is C(=O)NHCH<sub>3</sub>, and the combination of R<sup>1</sup> and (R<sup>3</sup>)<sub>n</sub> for a compound corresponds in each case to one row of Table A

## Table 11

Compounds of formula I.1\* in which R<sup>4</sup> is C(=O)NHC<sub>2</sub>H<sub>5</sub>, and the combination of R<sup>1</sup> and (R<sup>3</sup>)<sub>n</sub>

- 15 for a compound corresponds in each case to one row of Table A

## Table 12

Compounds of formula I.1\* in which R<sup>4</sup> is C(=O)N(CH<sub>3</sub>)<sub>2</sub>, and the combination of R<sup>1</sup> and (R<sup>3</sup>)<sub>n</sub> for a compound corresponds in each case to one row of Table A

## Table 13

- 20 Compounds of formula I.1\* in which R<sup>4</sup> is C(=O)N(CH<sub>3</sub>)C<sub>2</sub>H<sub>5</sub>, and the combination of R<sup>1</sup> and (R<sup>3</sup>)<sub>n</sub> for a compound corresponds in each case to one row of Table A

## Table 14

Compounds of formula I.1\* in which R<sup>4</sup> is C(=O)OCH<sub>3</sub>, and the combination of R<sup>1</sup> and (R<sup>3</sup>)<sub>n</sub> for a compound corresponds in each case to one row of Table A

- 25 Table 15

Compounds of formula I.1\* in which R<sup>4</sup> is C(=O)OC<sub>2</sub>H<sub>5</sub>, and the combination of R<sup>1</sup> and (R<sup>3</sup>)<sub>n</sub> for a compound corresponds in each case to one row of Table A

## Table 16

Compounds of formula I.1\* in which R<sup>4</sup> is CH<sub>2</sub>C(=O)NHCH<sub>3</sub>, and the combination of R<sup>1</sup> and

- 30 (R<sup>3</sup>)<sub>n</sub> for a compound corresponds in each case to one row of Table A

## Table 17

Compounds of formula I.1\* in which R<sup>4</sup> is 4,5-dihydrooxazol-2-yl, and the combination of R<sup>1</sup> and (R<sup>3</sup>)<sub>n</sub> for a compound corresponds in each case to one row of Table A

## Table 18

- 35 Compounds of formula I.1\* in which R<sup>4</sup> is SO<sub>2</sub>CH<sub>3</sub>, and the combination of R<sup>1</sup> and (R<sup>3</sup>)<sub>n</sub> for a compound corresponds in each case to one row of Table A

## Table 19

Compounds of formula I.1\* in which R<sup>4</sup> is SO<sub>2</sub>C<sub>2</sub>H<sub>5</sub>, and the combination of R<sup>1</sup> and (R<sup>3</sup>)<sub>n</sub> for a compound corresponds in each case to one row of Table A

## Table 20

- 5 Compounds of formula I.2\* in which R<sup>4</sup> is CN, and the combination of R<sup>1</sup> and (R<sup>3</sup>)<sub>n</sub> for a compound corresponds in each case to one row of Table A

## Table 21

Compounds of formula I.2\* in which R<sup>4</sup> is CH<sub>3</sub>, and the combination of R<sup>1</sup> and (R<sup>3</sup>)<sub>n</sub> for a compound corresponds in each case to one row of Table A

- 10 Table 22

Compounds of formula I.2\* in which R<sup>4</sup> is C<sub>2</sub>H<sub>5</sub>, and the combination of R<sup>1</sup> and (R<sup>3</sup>)<sub>n</sub> for a compound corresponds in each case to one row of Table A

## Table 23

- 15 Compounds of formula I.2\* in which R<sup>4</sup> is CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, and the combination of R<sup>1</sup> and (R<sup>3</sup>)<sub>n</sub> for a compound corresponds in each case to one row of Table A

## Table 24

Compounds of formula I.2\* in which R<sup>4</sup> is CH(CH<sub>3</sub>)<sub>2</sub>, and the combination of R<sup>1</sup> and (R<sup>3</sup>)<sub>n</sub> for a compound corresponds in each case to one row of Table A

## Table 25

- 20 Compounds of formula I.2\* in which R<sup>4</sup> is cC<sub>3</sub>H<sub>5</sub>, and the combination of R<sup>1</sup> and (R<sup>3</sup>)<sub>n</sub> for a compound corresponds in each case to one row of Table A

## Table 26

Compounds of formula I.2\* in which R<sup>4</sup> is CH<sub>2</sub>CF<sub>3</sub>, and the combination of R<sup>1</sup> and (R<sup>3</sup>)<sub>n</sub> for a compound corresponds in each case to one row of Table A

- 25 Table 27

Compounds of formula I.2\* in which R<sup>4</sup> is CH<sub>2</sub>OCH<sub>3</sub>, and the combination of R<sup>1</sup> and (R<sup>3</sup>)<sub>n</sub> for a compound corresponds in each case to one row of Table A

## Table 28

- 30 Compounds of formula I.2\* in which R<sup>4</sup> is C(=O)NH<sub>2</sub>, and the combination of R<sup>1</sup> and (R<sup>3</sup>)<sub>n</sub> for a compound corresponds in each case to one row of Table A

## Table 29

Compounds of formula I.2\* in which R<sup>4</sup> is C(=O)NHCH<sub>3</sub>, and the combination of R<sup>1</sup> and (R<sup>3</sup>)<sub>n</sub> for a compound corresponds in each case to one row of Table A

## Table 30

- 35 Compounds of formula I.2\* in which R<sup>4</sup> is C(=O)NHC<sub>2</sub>H<sub>5</sub>, and the combination of R<sup>1</sup> and (R<sup>3</sup>)<sub>n</sub> for a compound corresponds in each case to one row of Table A

Table 31

Compounds of formula I.2\* in which R<sup>4</sup> is C(=O)N(CH<sub>3</sub>)<sub>2</sub>, and the combination of R<sup>1</sup> and (R<sup>3</sup>)<sub>n</sub> for a compound corresponds in each case to one row of Table A

Table 32

- 5 Compounds of formula I.2\* in which R<sup>4</sup> is C(=O)N(CH<sub>3</sub>)C<sub>2</sub>H<sub>5</sub>, and the combination of R<sup>1</sup> and (R<sup>3</sup>)<sub>n</sub> for a compound corresponds in each case to one row of Table A

Table 33

Compounds of formula I.2\* in which R<sup>4</sup> is C(=O)OCH<sub>3</sub>, and the combination of R<sup>1</sup> and (R<sup>3</sup>)<sub>n</sub> for a compound corresponds in each case to one row of Table A

- 10 Table 34

Compounds of formula I.2\* in which R<sup>4</sup> is C(=O)OC<sub>2</sub>H<sub>5</sub>, and the combination of R<sup>1</sup> and (R<sup>3</sup>)<sub>n</sub> for a compound corresponds in each case to one row of Table A

Table 35

Compounds of formula I.2\* in which R<sup>4</sup> is CH<sub>2</sub>C(=O)NHCH<sub>3</sub>, and the combination of R<sup>1</sup> and

- 15 (R<sup>3</sup>)<sub>n</sub> for a compound corresponds in each case to one row of Table A

Table 36

Compounds of formula I.2\* in which R<sup>4</sup> is 4,5-dihydrooxazol-2-yl, and the combination of R<sup>1</sup> and (R<sup>3</sup>)<sub>n</sub> for a compound corresponds in each case to one row of Table A

Table 37

- 20 Compounds of formula I.2\* in which R<sup>4</sup> is SO<sub>2</sub>CH<sub>3</sub>, and the combination of R<sup>1</sup> and (R<sup>3</sup>)<sub>n</sub> for a compound corresponds in each case to one row of Table A

Table 38

Compounds of formula I.2\* in which R<sup>4</sup> is SO<sub>2</sub>C<sub>2</sub>H<sub>5</sub>, and the combination of R<sup>1</sup> and (R<sup>3</sup>)<sub>n</sub> for a compound corresponds in each case to one row of Table A

- 25

Table A

No.	R <sup>1</sup>	(R <sup>3</sup> ) <sub>n</sub>
A-1	H	3,5-F <sub>2</sub>
A-2	H	3,5-Cl <sub>2</sub>
A-3	H	3,5-Br <sub>2</sub>
A-4	H	3,5-I <sub>2</sub>
A-5	H	3,5-(CF <sub>3</sub> ) <sub>2</sub>
A-6	H	3-Cl,5-F
A-7	H	3-Cl,5-Br
A-8	H	3-Cl,5-I
A-9	H	3-F,5-CN
A-10	H	3-Cl,5-CN

No.	R <sup>1</sup>	(R <sup>3</sup> ) <sub>n</sub>
A-11	H	3-CF <sub>3</sub> ,5-CN
A-12	H	3-F,5-CF <sub>3</sub>
A-13	H	3-Cl,5-CF <sub>3</sub>
A-14	H	3-Br,5-CF <sub>3</sub>
A-15	H	3-I,5-CF <sub>3</sub>
A-16	H	3-Cl,5-SO <sub>2</sub> CH <sub>3</sub>
A-17	H	3-Cl,5-SO <sub>2</sub> CF <sub>3</sub>
A-18	H	3-Cl,5-cC <sub>3</sub> H <sub>5</sub>
A-19	H	3-Cl,5-[2,2-Cl <sub>2</sub> - cC <sub>3</sub> H <sub>3</sub> ]

No.	R <sup>1</sup>	(R <sup>3</sup> ) <sub>n</sub>
A-20	H	3-Cl,5-OCF <sub>3</sub>
A-21	H	3-Br,5-OCF <sub>3</sub>
A-22	H	3-F,5-cC <sub>3</sub> H <sub>5</sub>
A-23	H	3-Cl,5-CH <sub>2</sub> CN
A-24	H	3-Cl,5- C(CH <sub>3</sub> ) <sub>2</sub> CN
A-25	H	3-CF <sub>3</sub> ,5-CH <sub>2</sub> CN
A-26	H	3-CF <sub>3</sub> ,5- C(CH <sub>3</sub> ) <sub>2</sub> CN
A-27	H	3-CF <sub>3</sub> ,5-SO <sub>2</sub> CH <sub>3</sub>
A-28	H	3-CF <sub>3</sub> ,5-SO <sub>2</sub> CF <sub>3</sub>
A-29	H	3-CF <sub>3</sub> ,5-OCF <sub>3</sub>
A-30	H	3-CF <sub>3</sub> ,5-cC <sub>3</sub> H <sub>5</sub>
A-31	H	3-Cl,5-[(1- CN)cC <sub>3</sub> H <sub>4</sub> ]
A-32	H	3-CF <sub>3</sub> ,5-[(1- CN)cC <sub>3</sub> H <sub>4</sub> ]
A-33	H	3-CF <sub>3</sub> ,5-[(2,2- Cl <sub>2</sub> )-cC <sub>3</sub> H <sub>3</sub> ]
A-34	H	3-OCF <sub>3</sub> ,5-cC <sub>3</sub> H <sub>5</sub>
A-35	H	3,5-SO <sub>2</sub> CH <sub>3</sub>
A-36	H	3,5-SO <sub>2</sub> CF <sub>3</sub>
A-37	H	3-Cl,5-OC <sub>6</sub> H <sub>5</sub>
A-38	H	3-CF <sub>3</sub> ,5-OC <sub>6</sub> H <sub>5</sub>
A-39	H	3-CF <sub>3</sub> ,5-[O-(4- Cl-C <sub>6</sub> H <sub>4</sub> )]
A-40	CH <sub>3</sub>	3,5-F <sub>2</sub>
A-41	CH <sub>3</sub>	3,5-Cl <sub>2</sub>
A-42	CH <sub>3</sub>	3,5-Br <sub>2</sub>
A-43	CH <sub>3</sub>	3,5-I <sub>2</sub>
A-44	CH <sub>3</sub>	3,5-(CF <sub>3</sub> ) <sub>2</sub>
A-45	CH <sub>3</sub>	3-Cl,5-F
A-46	CH <sub>3</sub>	3-Cl,5-Br
A-47	CH <sub>3</sub>	3-Cl,5-I
A-48	CH <sub>3</sub>	3-F,5-CN

No.	R <sup>1</sup>	(R <sup>3</sup> ) <sub>n</sub>
A-49	CH <sub>3</sub>	3-Cl,5-CN
A-50	CH <sub>3</sub>	3-CF <sub>3</sub> ,5-CN
A-51	CH <sub>3</sub>	3-F,5-CF <sub>3</sub>
A-52	CH <sub>3</sub>	3-Cl,5-CF <sub>3</sub>
A-53	CH <sub>3</sub>	3-Br,5-CF <sub>3</sub>
A-54	CH <sub>3</sub>	3-I,5-CF <sub>3</sub>
A-55	CH <sub>3</sub>	3-Cl,5-SO <sub>2</sub> CH <sub>3</sub>
A-56	CH <sub>3</sub>	3-Cl,5-SO <sub>2</sub> CF <sub>3</sub>
A-57	CH <sub>3</sub>	3-Cl,5-cC <sub>3</sub> H <sub>5</sub>
A-58	CH <sub>3</sub>	3-Cl,5-[2,2-Cl <sub>2</sub> - cC <sub>3</sub> H <sub>3</sub> ]
A-59	CH <sub>3</sub>	3-Cl,5-OCF <sub>3</sub>
A-60	CH <sub>3</sub>	3-Br,5-OCF <sub>3</sub>
A-61	CH <sub>3</sub>	3-F,5-cC <sub>3</sub> H <sub>5</sub>
A-62	CH <sub>3</sub>	3-Cl,5-CH <sub>2</sub> CN
A-63	CH <sub>3</sub>	3-Cl,5- C(CH <sub>3</sub> ) <sub>2</sub> CN
A-64	CH <sub>3</sub>	3-CF <sub>3</sub> ,5-CH <sub>2</sub> CN
A-65	CH <sub>3</sub>	3-CF <sub>3</sub> ,5- C(CH <sub>3</sub> ) <sub>2</sub> CN
A-66	CH <sub>3</sub>	3-CF <sub>3</sub> ,5-SO <sub>2</sub> CH <sub>3</sub>
A-67	CH <sub>3</sub>	3-CF <sub>3</sub> ,5-SO <sub>2</sub> CF <sub>3</sub>
A-68	CH <sub>3</sub>	3-CF <sub>3</sub> ,5-OCF <sub>3</sub>
A-69	CH <sub>3</sub>	3-CF <sub>3</sub> ,5-cC <sub>3</sub> H <sub>5</sub>
A-70	CH <sub>3</sub>	3-Cl,5-[(1- CN)cC <sub>3</sub> H <sub>4</sub> ]
A-71	CH <sub>3</sub>	3-CF <sub>3</sub> ,5-[(1- CN)cC <sub>3</sub> H <sub>4</sub> ]
A-72	CH <sub>3</sub>	3-CF <sub>3</sub> ,5-[(2,2- Cl <sub>2</sub> )-cC <sub>3</sub> H <sub>3</sub> ]
A-73	CH <sub>3</sub>	3-OCF <sub>3</sub> ,5-cC <sub>3</sub> H <sub>5</sub>
A-74	CH <sub>3</sub>	3,5-SO <sub>2</sub> CH <sub>3</sub>
A-75	CH <sub>3</sub>	3,5-SO <sub>2</sub> CF <sub>3</sub>
A-76	CH <sub>3</sub>	3-Cl,5-OC <sub>6</sub> H <sub>5</sub>
A-77	CH <sub>3</sub>	3-CF <sub>3</sub> ,5-OC <sub>6</sub> H <sub>5</sub>

No.	R <sup>1</sup>	(R <sup>3</sup> ) <sub>n</sub>
A-78	CH <sub>3</sub>	3-CF <sub>3</sub> ,5-[O-(4-Cl-C <sub>6</sub> H <sub>4</sub> )]
A-79	C <sub>2</sub> H <sub>5</sub>	3,5-F <sub>2</sub>
A-80	C <sub>2</sub> H <sub>5</sub>	3,5-Cl <sub>2</sub>
A-81	C <sub>2</sub> H <sub>5</sub>	3,5-Br <sub>2</sub>
A-82	C <sub>2</sub> H <sub>5</sub>	3,5-I <sub>2</sub>
A-83	C <sub>2</sub> H <sub>5</sub>	3,5-(CF <sub>3</sub> ) <sub>2</sub>
A-84	C <sub>2</sub> H <sub>5</sub>	3-Cl,5-F
A-85	C <sub>2</sub> H <sub>5</sub>	3-Cl,5-Br
A-86	C <sub>2</sub> H <sub>5</sub>	3-Cl,5-I
A-87	C <sub>2</sub> H <sub>5</sub>	3-F,5-CN
A-88	C <sub>2</sub> H <sub>5</sub>	3-Cl,5-CN
A-89	C <sub>2</sub> H <sub>5</sub>	3-CF <sub>3</sub> ,5-CN
A-90	C <sub>2</sub> H <sub>5</sub>	3-F,5-CF <sub>3</sub>
A-91	C <sub>2</sub> H <sub>5</sub>	3-Cl,5-CF <sub>3</sub>
A-92	C <sub>2</sub> H <sub>5</sub>	3-Br,5-CF <sub>3</sub>
A-93	C <sub>2</sub> H <sub>5</sub>	3-I,5-CF <sub>3</sub>
A-94	C <sub>2</sub> H <sub>5</sub>	3-Cl,5-SO <sub>2</sub> CH <sub>3</sub>
A-95	C <sub>2</sub> H <sub>5</sub>	3-Cl,5-SO <sub>2</sub> CF <sub>3</sub>
A-96	C <sub>2</sub> H <sub>5</sub>	3-Cl,5-cC <sub>3</sub> H <sub>5</sub>
A-97	C <sub>2</sub> H <sub>5</sub>	3-Cl,5-[2,2-Cl <sub>2</sub> -cC <sub>3</sub> H <sub>3</sub> ]
A-98	C <sub>2</sub> H <sub>5</sub>	3-Cl,5-OCF <sub>3</sub>
A-99	C <sub>2</sub> H <sub>5</sub>	3-Br,5-OCF <sub>3</sub>
A-100	C <sub>2</sub> H <sub>5</sub>	3-F,5-cC <sub>3</sub> H <sub>5</sub>
A-101	C <sub>2</sub> H <sub>5</sub>	3-Cl,5-CH <sub>2</sub> CN
A-102	C <sub>2</sub> H <sub>5</sub>	3-Cl,5-C(CH <sub>3</sub> ) <sub>2</sub> CN
A-103	C <sub>2</sub> H <sub>5</sub>	3-CF <sub>3</sub> ,5-CH <sub>2</sub> CN
A-104	C <sub>2</sub> H <sub>5</sub>	3-CF <sub>3</sub> ,5-C(CH <sub>3</sub> ) <sub>2</sub> CN
A-105	C <sub>2</sub> H <sub>5</sub>	3-CF <sub>3</sub> ,5-SO <sub>2</sub> CH <sub>3</sub>
A-106	C <sub>2</sub> H <sub>5</sub>	3-CF <sub>3</sub> ,5-SO <sub>2</sub> CF <sub>3</sub>
A-107	C <sub>2</sub> H <sub>5</sub>	3-CF <sub>3</sub> ,5-OCF <sub>3</sub>
A-108	C <sub>2</sub> H <sub>5</sub>	3-CF <sub>3</sub> ,5-cC <sub>3</sub> H <sub>5</sub>

No.	R <sup>1</sup>	(R <sup>3</sup> ) <sub>n</sub>
A-109	C <sub>2</sub> H <sub>5</sub>	3-Cl,5-[(1-CN)cC <sub>3</sub> H <sub>4</sub> ]
A-110	C <sub>2</sub> H <sub>5</sub>	3-CF <sub>3</sub> ,5-[(1-CN)cC <sub>3</sub> H <sub>4</sub> ]
A-111	C <sub>2</sub> H <sub>5</sub>	3-CF <sub>3</sub> ,5-[(2,2-Cl <sub>2</sub> )-cC <sub>3</sub> H <sub>3</sub> ]
A-112	C <sub>2</sub> H <sub>5</sub>	3-OCF <sub>3</sub> ,5-cC <sub>3</sub> H <sub>5</sub>
A-113	C <sub>2</sub> H <sub>5</sub>	3,5-SO <sub>2</sub> CH <sub>3</sub>
A-114	C <sub>2</sub> H <sub>5</sub>	3,5-SO <sub>2</sub> CF <sub>3</sub>
A-115	C <sub>2</sub> H <sub>5</sub>	3-Cl,5-OC <sub>6</sub> H <sub>5</sub>
A-116	C <sub>2</sub> H <sub>5</sub>	3-CF <sub>3</sub> ,5-OC <sub>6</sub> H <sub>5</sub>
A-117	C <sub>2</sub> H <sub>5</sub>	3-CF <sub>3</sub> ,5-[O-(4-Cl-C <sub>6</sub> H <sub>4</sub> )]
A-118	CH <sub>2</sub> -cC <sub>3</sub> H <sub>5</sub>	3,5-F <sub>2</sub>
A-119	CH <sub>2</sub> -cC <sub>3</sub> H <sub>5</sub>	3,5-Cl <sub>2</sub>
A-120	CH <sub>2</sub> -cC <sub>3</sub> H <sub>5</sub>	3,5-Br <sub>2</sub>
A-121	CH <sub>2</sub> -cC <sub>3</sub> H <sub>5</sub>	3,5-I <sub>2</sub>
A-122	CH <sub>2</sub> -cC <sub>3</sub> H <sub>5</sub>	3,5-(CF <sub>3</sub> ) <sub>2</sub>
A-123	CH <sub>2</sub> -cC <sub>3</sub> H <sub>5</sub>	3-Cl,5-F
A-124	CH <sub>2</sub> -cC <sub>3</sub> H <sub>5</sub>	3-Cl,5-Br
A-125	CH <sub>2</sub> -cC <sub>3</sub> H <sub>5</sub>	3-Cl,5-I
A-126	CH <sub>2</sub> -cC <sub>3</sub> H <sub>5</sub>	3-F,5-CN
A-127	CH <sub>2</sub> -cC <sub>3</sub> H <sub>5</sub>	3-Cl,5-CN
A-128	CH <sub>2</sub> -cC <sub>3</sub> H <sub>5</sub>	3-CF <sub>3</sub> ,5-CN
A-129	CH <sub>2</sub> -cC <sub>3</sub> H <sub>5</sub>	3-F,5-CF <sub>3</sub>
A-130	CH <sub>2</sub> -cC <sub>3</sub> H <sub>5</sub>	3-Cl,5-CF <sub>3</sub>
A-131	CH <sub>2</sub> -cC <sub>3</sub> H <sub>5</sub>	3-Br,5-CF <sub>3</sub>
A-132	CH <sub>2</sub> -cC <sub>3</sub> H <sub>5</sub>	3-I,5-CF <sub>3</sub>
A-133	CH <sub>2</sub> -cC <sub>3</sub> H <sub>5</sub>	3-Cl,5-SO <sub>2</sub> CH <sub>3</sub>
A-134	CH <sub>2</sub> -cC <sub>3</sub> H <sub>5</sub>	3-Cl,5-SO <sub>2</sub> CF <sub>3</sub>
A-135	CH <sub>2</sub> -cC <sub>3</sub> H <sub>5</sub>	3-Cl,5-cC <sub>3</sub> H <sub>5</sub>
A-136	CH <sub>2</sub> -cC <sub>3</sub> H <sub>5</sub>	3-Cl,5-[2,2-Cl <sub>2</sub> -cC <sub>3</sub> H <sub>3</sub> ]
A-137	CH <sub>2</sub> -cC <sub>3</sub> H <sub>5</sub>	3-Cl,5-OCF <sub>3</sub>
A-138	CH <sub>2</sub> -cC <sub>3</sub> H <sub>5</sub>	3-Br,5-OCF <sub>3</sub>

No.	R <sup>1</sup>	(R <sup>3</sup> ) <sub>n</sub>
A-139	CH <sub>2</sub> -cC <sub>3</sub> H <sub>5</sub>	3-F,5-cC <sub>3</sub> H <sub>5</sub>
A-140	CH <sub>2</sub> -cC <sub>3</sub> H <sub>5</sub>	3-Cl,5-CH <sub>2</sub> CN
A-141	CH <sub>2</sub> -cC <sub>3</sub> H <sub>5</sub>	3-Cl,5- C(CH <sub>3</sub> ) <sub>2</sub> CN
A-142	CH <sub>2</sub> -cC <sub>3</sub> H <sub>5</sub>	3-CF <sub>3</sub> ,5-CH <sub>2</sub> CN
A-143	CH <sub>2</sub> -cC <sub>3</sub> H <sub>5</sub>	3-CF <sub>3</sub> ,5- C(CH <sub>3</sub> ) <sub>2</sub> CN
A-144	CH <sub>2</sub> -cC <sub>3</sub> H <sub>5</sub>	3-CF <sub>3</sub> ,5-SO <sub>2</sub> CH <sub>3</sub>
A-145	CH <sub>2</sub> -cC <sub>3</sub> H <sub>5</sub>	3-CF <sub>3</sub> ,5-SO <sub>2</sub> CF <sub>3</sub>
A-146	CH <sub>2</sub> -cC <sub>3</sub> H <sub>5</sub>	3-CF <sub>3</sub> ,5-OCF <sub>3</sub>
A-147	CH <sub>2</sub> -cC <sub>3</sub> H <sub>5</sub>	3-CF <sub>3</sub> ,5-cC <sub>3</sub> H <sub>5</sub>
A-148	CH <sub>2</sub> -cC <sub>3</sub> H <sub>5</sub>	3-Cl,5-[(1- CN)cC <sub>3</sub> H <sub>4</sub> ]
A-149	CH <sub>2</sub> -cC <sub>3</sub> H <sub>5</sub>	3-CF <sub>3</sub> ,5-[(1- CN)cC <sub>3</sub> H <sub>4</sub> ]
A-150	CH <sub>2</sub> -cC <sub>3</sub> H <sub>5</sub>	3-CF <sub>3</sub> ,5-[(2,2- Cl <sub>2</sub> )-cC <sub>3</sub> H <sub>3</sub> ]
A-151	CH <sub>2</sub> -cC <sub>3</sub> H <sub>5</sub>	3-OCF <sub>3</sub> ,5-cC <sub>3</sub> H <sub>5</sub>
A-152	CH <sub>2</sub> -cC <sub>3</sub> H <sub>5</sub>	3,5-SO <sub>2</sub> CH <sub>3</sub>
A-153	CH <sub>2</sub> -cC <sub>3</sub> H <sub>5</sub>	3,5-SO <sub>2</sub> CF <sub>3</sub>
A-154	CH <sub>2</sub> -cC <sub>3</sub> H <sub>5</sub>	3-Cl,5-OC <sub>6</sub> H <sub>5</sub>
A-155	CH <sub>2</sub> -cC <sub>3</sub> H <sub>5</sub>	3-CF <sub>3</sub> ,5-OC <sub>6</sub> H <sub>5</sub>
A-156	CH <sub>2</sub> -cC <sub>3</sub> H <sub>5</sub>	3-CF <sub>3</sub> ,5-[O-(4- Cl-C <sub>6</sub> H <sub>4</sub> )]
A-157	CH <sub>2</sub> -cC <sub>5</sub> H <sub>9</sub>	3,5-F <sub>2</sub>
A-158	CH <sub>2</sub> -cC <sub>5</sub> H <sub>9</sub>	3,5-Cl <sub>2</sub>
A-159	CH <sub>2</sub> -cC <sub>5</sub> H <sub>9</sub>	3,5-Br <sub>2</sub>
A-160	CH <sub>2</sub> -cC <sub>5</sub> H <sub>9</sub>	3,5-I <sub>2</sub>
A-161	CH <sub>2</sub> -cC <sub>5</sub> H <sub>9</sub>	3,5-(CF <sub>3</sub> ) <sub>2</sub>
A-162	CH <sub>2</sub> -cC <sub>5</sub> H <sub>9</sub>	3-Cl,5-F
A-163	CH <sub>2</sub> -cC <sub>5</sub> H <sub>9</sub>	3-Cl,5-Br
A-164	CH <sub>2</sub> -cC <sub>5</sub> H <sub>9</sub>	3-Cl,5-I
A-165	CH <sub>2</sub> -cC <sub>5</sub> H <sub>9</sub>	3-F,5-CN
A-166	CH <sub>2</sub> -cC <sub>5</sub> H <sub>9</sub>	3-Cl,5-CN
A-167	CH <sub>2</sub> -cC <sub>5</sub> H <sub>9</sub>	3-CF <sub>3</sub> ,5-CN

No.	R <sup>1</sup>	(R <sup>3</sup> ) <sub>n</sub>
A-168	CH <sub>2</sub> -cC <sub>5</sub> H <sub>9</sub>	3-F,5-CF <sub>3</sub>
A-169	CH <sub>2</sub> -cC <sub>5</sub> H <sub>9</sub>	3-Cl,5-CF <sub>3</sub>
A-170	CH <sub>2</sub> -cC <sub>5</sub> H <sub>9</sub>	3-Br,5-CF <sub>3</sub>
A-171	CH <sub>2</sub> -cC <sub>5</sub> H <sub>9</sub>	3-I,5-CF <sub>3</sub>
A-172	CH <sub>2</sub> -cC <sub>5</sub> H <sub>9</sub>	3-Cl,5-SO <sub>2</sub> CH <sub>3</sub>
A-173	CH <sub>2</sub> -cC <sub>5</sub> H <sub>9</sub>	3-Cl,5-SO <sub>2</sub> CF <sub>3</sub>
A-174	CH <sub>2</sub> -cC <sub>5</sub> H <sub>9</sub>	3-Cl,5-cC <sub>3</sub> H <sub>5</sub>
A-175	CH <sub>2</sub> -cC <sub>5</sub> H <sub>9</sub>	3-Cl,5-[2,2-Cl <sub>2</sub> - cC <sub>3</sub> H <sub>3</sub> ]
A-176	CH <sub>2</sub> -cC <sub>5</sub> H <sub>9</sub>	3-Cl,5-OCF <sub>3</sub>
A-177	CH <sub>2</sub> -cC <sub>5</sub> H <sub>9</sub>	3-Br,5-OCF <sub>3</sub>
A-178	CH <sub>2</sub> -cC <sub>5</sub> H <sub>9</sub>	3-F,5-cC <sub>3</sub> H <sub>5</sub>
A-179	CH <sub>2</sub> -cC <sub>5</sub> H <sub>9</sub>	3-Cl,5-CH <sub>2</sub> CN
A-180	CH <sub>2</sub> -cC <sub>5</sub> H <sub>9</sub>	3-Cl,5- C(CH <sub>3</sub> ) <sub>2</sub> CN
A-181	CH <sub>2</sub> -cC <sub>5</sub> H <sub>9</sub>	3-CF <sub>3</sub> ,5-CH <sub>2</sub> CN
A-182	CH <sub>2</sub> -cC <sub>5</sub> H <sub>9</sub>	3-CF <sub>3</sub> ,5- C(CH <sub>3</sub> ) <sub>2</sub> CN
A-183	CH <sub>2</sub> -cC <sub>5</sub> H <sub>9</sub>	3-CF <sub>3</sub> ,5-SO <sub>2</sub> CH <sub>3</sub>
A-184	CH <sub>2</sub> -cC <sub>5</sub> H <sub>9</sub>	3-CF <sub>3</sub> ,5-SO <sub>2</sub> CF <sub>3</sub>
A-185	CH <sub>2</sub> -cC <sub>5</sub> H <sub>9</sub>	3-CF <sub>3</sub> ,5-OCF <sub>3</sub>
A-186	CH <sub>2</sub> -cC <sub>5</sub> H <sub>9</sub>	3-CF <sub>3</sub> ,5-cC <sub>3</sub> H <sub>5</sub>
A-187	CH <sub>2</sub> -cC <sub>5</sub> H <sub>9</sub>	3-Cl,5-[(1- CN)cC <sub>3</sub> H <sub>4</sub> ]
A-188	CH <sub>2</sub> -cC <sub>5</sub> H <sub>9</sub>	3-CF <sub>3</sub> ,5-[(1- CN)cC <sub>3</sub> H <sub>4</sub> ]
A-189	CH <sub>2</sub> -cC <sub>5</sub> H <sub>9</sub>	3-CF <sub>3</sub> ,5-[(2,2- Cl <sub>2</sub> )-cC <sub>3</sub> H <sub>3</sub> ]
A-190	CH <sub>2</sub> -cC <sub>5</sub> H <sub>9</sub>	3-OCF <sub>3</sub> ,5-cC <sub>3</sub> H <sub>5</sub>
A-191	CH <sub>2</sub> -cC <sub>5</sub> H <sub>9</sub>	3,5-SO <sub>2</sub> CH <sub>3</sub>
A-192	CH <sub>2</sub> -cC <sub>5</sub> H <sub>9</sub>	3,5-SO <sub>2</sub> CF <sub>3</sub>
A-193	CH <sub>2</sub> -cC <sub>5</sub> H <sub>9</sub>	3-Cl,5-OC <sub>6</sub> H <sub>5</sub>
A-194	CH <sub>2</sub> -cC <sub>5</sub> H <sub>9</sub>	3-CF <sub>3</sub> ,5-OC <sub>6</sub> H <sub>5</sub>
A-195	CH <sub>2</sub> -cC <sub>5</sub> H <sub>9</sub>	3-CF <sub>3</sub> ,5-[O-(4- Cl-C <sub>6</sub> H <sub>4</sub> )]

No.	R <sup>1</sup>	(R <sup>3</sup> ) <sub>n</sub>
A-196	CH <sub>2</sub> CH=CH <sub>2</sub>	3,5-F <sub>2</sub>
A-197	CH <sub>2</sub> CH=CH <sub>2</sub>	3,5-Cl <sub>2</sub>
A-198	CH <sub>2</sub> CH=CH <sub>2</sub>	3,5-Br <sub>2</sub>
A-199	CH <sub>2</sub> CH=CH <sub>2</sub>	3,5-I <sub>2</sub>
A-200	CH <sub>2</sub> CH=CH <sub>2</sub>	3,5-(CF <sub>3</sub> ) <sub>2</sub>
A-201	CH <sub>2</sub> CH=CH <sub>2</sub>	3-Cl,5-F
A-202	CH <sub>2</sub> CH=CH <sub>2</sub>	3-Cl,5-Br
A-203	CH <sub>2</sub> CH=CH <sub>2</sub>	3-Cl,5-I
A-204	CH <sub>2</sub> CH=CH <sub>2</sub>	3-F,5-CN
A-205	CH <sub>2</sub> CH=CH <sub>2</sub>	3-Cl,5-CN
A-206	CH <sub>2</sub> CH=CH <sub>2</sub>	3-CF <sub>3</sub> ,5-CN
A-207	CH <sub>2</sub> CH=CH <sub>2</sub>	3-F,5-CF <sub>3</sub>
A-208	CH <sub>2</sub> CH=CH <sub>2</sub>	3-Cl,5-CF <sub>3</sub>
A-209	CH <sub>2</sub> CH=CH <sub>2</sub>	3-Br,5-CF <sub>3</sub>
A-210	CH <sub>2</sub> CH=CH <sub>2</sub>	3-I,5-CF <sub>3</sub>
A-211	CH <sub>2</sub> CH=CH <sub>2</sub>	3-Cl,5-SO <sub>2</sub> CH <sub>3</sub>
A-212	CH <sub>2</sub> CH=CH <sub>2</sub>	3-Cl,5-SO <sub>2</sub> CF <sub>3</sub>
A-213	CH <sub>2</sub> CH=CH <sub>2</sub>	3-Cl,5-cC <sub>3</sub> H <sub>5</sub>
A-214	CH <sub>2</sub> CH=CH <sub>2</sub>	3-Cl,5-[2,2-Cl <sub>2</sub> - cC <sub>3</sub> H <sub>3</sub> ]
A-215	CH <sub>2</sub> CH=CH <sub>2</sub>	3-Cl,5-OCF <sub>3</sub>
A-216	CH <sub>2</sub> CH=CH <sub>2</sub>	3-Br,5-OCF <sub>3</sub>
A-217	CH <sub>2</sub> CH=CH <sub>2</sub>	3-F,5-cC <sub>3</sub> H <sub>5</sub>
A-218	CH <sub>2</sub> CH=CH <sub>2</sub>	3-Cl,5-CH <sub>2</sub> CN
A-219	CH <sub>2</sub> CH=CH <sub>2</sub>	3-Cl,5- C(CH <sub>3</sub> ) <sub>2</sub> CN
A-220	CH <sub>2</sub> CH=CH <sub>2</sub>	3-CF <sub>3</sub> ,5-CH <sub>2</sub> CN
A-221	CH <sub>2</sub> CH=CH <sub>2</sub>	3-CF <sub>3</sub> ,5- C(CH <sub>3</sub> ) <sub>2</sub> CN
A-222	CH <sub>2</sub> CH=CH <sub>2</sub>	3-CF <sub>3</sub> ,5-SO <sub>2</sub> CH <sub>3</sub>
A-223	CH <sub>2</sub> CH=CH <sub>2</sub>	3-CF <sub>3</sub> ,5-SO <sub>2</sub> CF <sub>3</sub>
A-224	CH <sub>2</sub> CH=CH <sub>2</sub>	3-CF <sub>3</sub> ,5-OCF <sub>3</sub>
A-225	CH <sub>2</sub> CH=CH <sub>2</sub>	3-CF <sub>3</sub> ,5-cC <sub>3</sub> H <sub>5</sub>
A-226	CH <sub>2</sub> CH=CH <sub>2</sub>	3-Cl,5-[(1- CN)cC <sub>3</sub> H <sub>4</sub> ]

No.	R <sup>1</sup>	(R <sup>3</sup> ) <sub>n</sub>
A-227	CH <sub>2</sub> CH=CH <sub>2</sub>	3-CF <sub>3</sub> ,5-[(1- CN)cC <sub>3</sub> H <sub>4</sub> ]
A-228	CH <sub>2</sub> CH=CH <sub>2</sub>	3-CF <sub>3</sub> ,5-[(2,2- Cl <sub>2</sub> )-cC <sub>3</sub> H <sub>3</sub> ]
A-229	CH <sub>2</sub> CH=CH <sub>2</sub>	3-OCF <sub>3</sub> ,5-cC <sub>3</sub> H <sub>5</sub>
A-230	CH <sub>2</sub> CH=CH <sub>2</sub>	3,5-SO <sub>2</sub> CH <sub>3</sub>
A-231	CH <sub>2</sub> CH=CH <sub>2</sub>	3,5-SO <sub>2</sub> CF <sub>3</sub>
A-232	CH <sub>2</sub> CH=CH <sub>2</sub>	3-Cl,5-OC <sub>6</sub> H <sub>5</sub>
A-233	CH <sub>2</sub> CH=CH <sub>2</sub>	3-CF <sub>3</sub> ,5-OC <sub>6</sub> H <sub>5</sub>
A-234	CH <sub>2</sub> CH=CH <sub>2</sub>	3-CF <sub>3</sub> ,5-[O-(4- Cl-C <sub>6</sub> H <sub>4</sub> )]
A-235	CH <sub>2</sub> C≡CH	3,5-F <sub>2</sub>
A-236	CH <sub>2</sub> C≡CH	3,5-Cl <sub>2</sub>
A-237	CH <sub>2</sub> C≡CH	3,5-Br <sub>2</sub>
A-238	CH <sub>2</sub> C≡CH	3,5-I <sub>2</sub>
A-239	CH <sub>2</sub> C≡CH	3,5-(CF <sub>3</sub> ) <sub>2</sub>
A-240	CH <sub>2</sub> C≡CH	3-Cl,5-F
A-241	CH <sub>2</sub> C≡CH	3-Cl,5-Br
A-242	CH <sub>2</sub> C≡CH	3-Cl,5-I
A-243	CH <sub>2</sub> C≡CH	3-F,5-CN
A-244	CH <sub>2</sub> C≡CH	3-Cl,5-CN
A-245	CH <sub>2</sub> C≡CH	3-CF <sub>3</sub> ,5-CN
A-246	CH <sub>2</sub> C≡CH	3-F,5-CF <sub>3</sub>
A-247	CH <sub>2</sub> C≡CH	3-Cl,5-CF <sub>3</sub>
A-248	CH <sub>2</sub> C≡CH	3-Br,5-CF <sub>3</sub>
A-249	CH <sub>2</sub> C≡CH	3-I,5-CF <sub>3</sub>
A-250	CH <sub>2</sub> C≡CH	3-Cl,5-SO <sub>2</sub> CH <sub>3</sub>
A-251	CH <sub>2</sub> C≡CH	3-Cl,5-SO <sub>2</sub> CF <sub>3</sub>
A-252	CH <sub>2</sub> C≡CH	3-Cl,5-cC <sub>3</sub> H <sub>5</sub>
A-253	CH <sub>2</sub> C≡CH	3-Cl,5-[2,2-Cl <sub>2</sub> - cC <sub>3</sub> H <sub>3</sub> ]
A-254	CH <sub>2</sub> C≡CH	3-Cl,5-OCF <sub>3</sub>
A-255	CH <sub>2</sub> C≡CH	3-Br,5-OCF <sub>3</sub>
A-256	CH <sub>2</sub> C≡CH	3-F,5-cC <sub>3</sub> H <sub>5</sub>
A-257	CH <sub>2</sub> C≡CH	3-Cl,5-CH <sub>2</sub> CN

No.	R <sup>1</sup>	(R <sup>3</sup> ) <sub>n</sub>
A-258	CH <sub>2</sub> C≡CH	3-Cl,5-C(CH <sub>3</sub> ) <sub>2</sub> CN
A-259	CH <sub>2</sub> C≡CH	3-CF <sub>3</sub> ,5-CH <sub>2</sub> CN
A-260	CH <sub>2</sub> C≡CH	3-CF <sub>3</sub> ,5-C(CH <sub>3</sub> ) <sub>2</sub> CN
A-261	CH <sub>2</sub> C≡CH	3-CF <sub>3</sub> ,5-SO <sub>2</sub> CH <sub>3</sub>
A-262	CH <sub>2</sub> C≡CH	3-CF <sub>3</sub> ,5-SO <sub>2</sub> CF <sub>3</sub>
A-263	CH <sub>2</sub> C≡CH	3-CF <sub>3</sub> ,5-OCF <sub>3</sub>
A-264	CH <sub>2</sub> C≡CH	3-CF <sub>3</sub> ,5-cC <sub>3</sub> H <sub>5</sub>
A-265	CH <sub>2</sub> C≡CH	3-Cl,5-[(1-CN)cC <sub>3</sub> H <sub>4</sub> ]

No.	R <sup>1</sup>	(R <sup>3</sup> ) <sub>n</sub>
A-266	CH <sub>2</sub> C≡CH	3-CF <sub>3</sub> ,5-[(1-CN)cC <sub>3</sub> H <sub>4</sub> ]
A-267	CH <sub>2</sub> C≡CH	3-CF <sub>3</sub> ,5-[(2,2-Cl <sub>2</sub> )-cC <sub>3</sub> H <sub>3</sub> ]
A-268	CH <sub>2</sub> C≡CH	3-OCF <sub>3</sub> ,5-cC <sub>3</sub> H <sub>5</sub>
A-269	CH <sub>2</sub> C≡CH	3,5-SO <sub>2</sub> CH <sub>3</sub>
A-270	CH <sub>2</sub> C≡CH	3,5-SO <sub>2</sub> CF <sub>3</sub>
A-271	CH <sub>2</sub> C≡CH	3-Cl,5-OC <sub>6</sub> H <sub>5</sub>
A-272	CH <sub>2</sub> C≡CH	3-CF <sub>3</sub> ,5-OC <sub>6</sub> H <sub>5</sub>
A-273	CH <sub>2</sub> C≡CH	3-CF <sub>3</sub> ,5-[O-(4-Cl-C <sub>6</sub> H <sub>4</sub> )]

The term “compound(s) of the invention” refers to compound(s) of formula I, or “compound(s) I”, and includes their salts, tautomers, stereoisomers, and N-oxides.

5

The invention also relates to agrochemical compositions comprising an auxiliary and at least one compound I.

An agrochemical composition comprises a pesticidally effective amount of a compound I.

An agrochemical composition comprises a pesticidally effective amount of a compound I.

10 The compounds I can be converted into customary types of agro-chemical compositions, e.g. solutions, emulsions, suspensions, dusts, powders, pastes, granules, pressings, capsules, and mixtures thereof. Examples for composition types are suspensions (e.g. SC, OD, FS), emulsifiable concentrates (e.g. EC), emulsions (e.g. EW, EO, ES, ME), capsules (e.g. CS, ZC), pastes, pastilles, wettable powders or dusts (e.g. WP, SP, WS, DP, DS), pressings (e.g. BR, TB, DT),  
 15 granules (e.g. WG, SG, GR, FG, GG, MG), insecticidal articles (e.g. LN), as well as gel formulations for the treatment of plant propagation materials e.g. seeds (e.g. GF). These and further compositions types are defined in the “Catalogue of pesticide formulation types and international coding system”, Technical Monograph No. 2, 6th Ed. May 2008, CropLife International.

Suitable auxiliaries are solvents, liquid carriers, solid carriers or fillers, surfactants, dispersants, emulsifiers, wetters, adjuvants, solubilizers, penetration enhancers, protective colloids, adhesion agents, thickeners, humectants, repellents, attractants, feeding stimulants, compatibilizers, bactericides, anti-freezing agents, anti-foaming agents, colorants, tackifiers and binders.

20 Suitable solvents and liquid carriers are water and organic solvents. Suitable solid carriers or fillers are mineral earths.

Suitable surfactants are surface-active compounds, e.g. anionic, cationic, nonionic, and amphoteric surfactants, block polymers, polyelectrolytes. Such surfactants can be used as emulsifier, dispersant, solubilizer, wetter, penetration enhancer, protective colloid, or adjuvant. Surfactants are listed in McCutcheon's, Vol.1: Emulsifiers & Detergents, McCutcheon's Directories, 5 Glen Rock, USA, 2008 (International or North American Ed.). Suitable anionic surfactants are alkali, alkaline earth, or ammonium salts of sulfonates, sulfates, phosphates, carboxylates. Suitable nonionic surfactants are alkoxyates, N-substituted fatty acid amides, amine oxides, esters, sugar-based surfactants, polymeric surfactants. Suitable cationic surfactants are quaternary surfactants.

10 The agrochemical compositions generally comprise between 0.01 and 95%, preferably between 0.1 and 90%, and most preferably between 0.5 and 75%, by weight of active substance. The active substances are employed in a purity of from 90% to 100%, preferably from 95% to 100%.

15 Various types of oils, wetters, adjuvants, or fertilizer may be added to the active substances or the compositions comprising them as premix or, if appropriate not until immediately prior to use (tank mix). These agents can be admixed with the compositions according to the invention in a weight ratio of 1:100 to 100:1.

20 The user applies the composition according to the invention usually from a predosage device, a knapsack sprayer, a spray tank, a spray plane, or an irrigation system. Usually, the agrochemical composition is made up with water, buffer, and/or further auxiliaries to the desired application concentration and the ready-to-use spray liquor or the agrochemical composition according to the invention is thus obtained. Usually, 20 to 2000 liters of the ready-to-use spray liquor are applied per hectare of agricultural useful area.

25 The compounds I are suitable for use in protecting crops, plants, plant propagation materials, e.g. seeds, or soil or water, in which the plants are growing, from attack or infestation by animal pests. Therefore, the invention also relates to a plant protection method, which comprises contacting crops, plants, plant propagation materials, e.g. seeds, or soil or water, in which the plants are growing, to be protected from attack or infestation by animal pests, with a pesticidally 30 effective amount of a compound I.

The compounds I are also suitable for use in combating or controlling animal pests. Therefore, the invention also relates to a method of combating or controlling animal pests, which comprises contacting the animal pests, their habitat, breeding ground, or food supply, or the crops, plants, plant propagation materials, e.g. seeds, or soil, or the area, material or environment in which the 35 animal pests are growing or may grow, with a pesticidally effective amount of a compound I.

The compounds I are effective through both contact and ingestion to any and all developmental stages, such as egg, larva, pupa, and adult.

The compounds I can be applied as such or in form of compositions comprising them.

The application can be carried out both before and after the infestation of the crops, plants, plant propagation materials by the pests.

5 The term "contacting" includes both direct contact (applying the compounds/compositions directly on the animal pest or plant) and indirect contact (applying the compounds/compositions to the locus).

The term "animal pest" includes arthropods, gastropods, and nematodes. Preferred animal pests according to the invention are arthropods, preferably insects and arachnids, in particular insects.

10 The term "plant" includes cereals, e.g. durum and other wheat, rye, barley, triticale, oats, rice, or maize (fodder maize and sugar maize / sweet and field corn); beet, e.g. sugar beet, or fodder beet; fruits, e.g. pomes, stone fruits, or soft fruits, e.g. apples, pears, plums, peaches, nectarines, almonds, cherries, papayas, strawberries, raspberries, blackberries or gooseberries; leguminous plants, e.g. beans, lentils, peas, alfalfa, or soybeans; oil plants, e.g. rapeseed (oilseed  
15 rape), turnip rape, mustard, olives, sunflowers, coconut, cocoa beans, castor oil plants, oil palms, ground nuts, or soybeans; cucurbits, e.g. squashes, pumpkins, cucumber or melons; fiber plants, e.g. cotton, flax, hemp, or jute; citrus fruit, e.g. oranges, lemons, grapefruits or mandarins; vegetables, e.g. eggplant, spinach, lettuce (e.g. iceberg lettuce), chicory, cabbage, asparagus, cabbages, carrots, onions, garlic, leeks, tomatoes, potatoes, cucurbits or sweet peppers;  
20 lauraceous plants, e.g. avocados, cinnamon, or camphor; energy and raw material plants, e.g. corn, soybean, rapeseed, sugar cane or oil palm; tobacco; nuts, e.g. walnuts; pistachios; coffee; tea; bananas; vines; hop; sweet leaf (Stevia); natural rubber plants or ornamental and forestry plants, shrubs, broad-leaved trees or evergreens, eucalyptus; turf; lawn; grass. Preferred plants include potatoes, sugar beets, tobacco, wheat, rye, barley, oats, rice, corn, cotton,  
25 soybeans, rapeseed, legumes, sunflowers, coffee, or sugar cane; fruits; vines; ornamentals; or vegetables, e.g. cucumbers, tomatoes, beans or squashes.

The term "seed" embraces seeds and plant propagules including true seeds, seed pieces, suckers, corms, bulbs, fruit, tubers, grains, cuttings, cut shoots, and means preferably true seeds.

30 "Pesticidally effective amount" means the amount of active ingredient needed to achieve an observable effect on growth, including the effects of necrosis, death, retardation, prevention, and removal, destruction, or otherwise diminishing the occurrence and activity of the target organism. The pesticidally effective amount can vary for the various compounds/compositions used in the invention. A pesticidally effective amount of the compositions will also vary according to the prevailing conditions e.g. desired pesticidal effect and duration, weather, target species,  
35 locus, mode of application.

For use in treating crop plants, e.g. by foliar application, the rate of application of the active ingredients of this invention may be in the range of 0.0001 g to 4000 g per hectare, e.g. from 1 g to 2 kg per hectare or from 1 g to 750 g per hectare, desirably from 1 g to 100 g per hectare.

5 The compounds I are also suitable for use against non-crop insect pests. For use against said non-crop pests, compounds I can be used as bait composition, gel, general insect spray, aerosol, as ultra-low volume application and bed net (impregnated or surface applied).

The term "non-crop insect pest" refers to pests, which are particularly relevant for non-crop targets, e.g. ants, termites, wasps, flies, ticks, mosquitoes, bed bugs, crickets, or cockroaches, such as: *Aedes aegypti*, *Musca domestica*, *Tribolium spp.*; termites such as *Reticulitermes flavipes*, *Coptotermes formosanus*; roaches such as *Blatella germanica*, *Periplaneta Americana*; ants such as *Solenopsis invicta*, *Linepithema humile*, and *Camponotus pennsylvanicus*.

10 The bait can be a liquid, a solid or a semisolid preparation (e.g. a gel). For use in bait compositions, the typical content of active ingredient is from 0.001 wt% to 15 wt%, desirably from 0.001 wt% to 5 wt% of active compound.

The compounds I and its compositions can be used for protecting wooden materials such as trees, board fences, sleepers, frames, artistic artifacts, etc. and buildings, but also construction materials, furniture, leathers, fibers, vinyl articles, electric wires and cables etc. from ants, termites and/or wood or textile destroying beetles, and for controlling ants and termites from doing harm to crops or human beings (e.g. when the pests invade into houses and public facilities or nest in yards, orchards or parks).

15 Customary application rates in the protection of materials are, e.g., from 0.001 g to 2000 g or from 0.01 g to 1000 g of active compound per m<sup>2</sup> treated material, desirably from 0.1 g to 50 g per m<sup>2</sup>.

25 Insecticidal compositions for use in the impregnation of materials typically contain from 0.001 to 95 wt%, preferably from 0.1 to 45 wt%, and more preferably from 1 to 25 wt% of at least one repellent and/or insecticide.

The compounds of the invention are especially suitable for efficiently combating animal pests e.g. arthropods, and nematodes including:

30 insects from the sub-order of Auchenorrhyncha, e.g. *Amrasca biguttula*, *Empoasca spp.*, *Nephotettix virescens*, *Sogatella furcifera*, *Mahanarva spp.*, *Laodelphax striatellus*, *Nilaparvata lugens*, *Diaphorina citri*;

Lepidoptera, e.g. *Helicoverpa spp.*, *Heliothis virescens*, *Lobesia botrana*, *Ostrinia nubilalis*, *Plutella xylostella*, *Pseudoplusia includens*, *Scirpophaga incertulas*, *Spodoptera spp.*, *Trichoplusia ni*, *Tuta absoluta*, *Cnaphalocrocis medialis*, *Cydia pomonella*, *Chilo suppressalis*, *Anticarsia gemmatalis*, *Agrotis ipsilon*, *Chrysodeixis includens*;

True bugs, e.g. *Lygus* spp., Stink bugs such as *Euschistus* spp., *Halyomorpha halys*, *Nezara viridula*, *Piezodorus guildinii*, *Dichelops furcatus*;

Thrips, e.g. *Frankliniella* spp., *Thrips* spp., *Dichromothrips corbettii*;

Aphids, e.g. *Acyrtosiphon pisum*, *Aphis* spp., *Myzus persicae*, *Rhopalosiphum* spp., *Schizaphis graminum*, *Megoura viciae*;

Whiteflies, e.g. *Trialeurodes vaporariorum*, *Bemisia* spp.;

Coleoptera, e.g. *Phyllotreta* spp., *Melanotus* spp., *Meligethes aeneus*, *Leptinotarsa decimlineata*, *Ceutorhynchus* spp., *Diabrotica* spp., *Anthonomus grandis*, *Atomaria linearia*, *Agriotes* spp., *Epilachna* spp.;

Flies, e.g. *Delia* spp., *Ceratitis capitata*, *Bactrocera* spp., *Liriomyza* spp.;

Mosquitoes (Diptera), e.g. *Aedes aegypti*, *A. albopictus*, *A. vexans*, *Anastrepha ludens*, *Anopheles maculipennis*, *A. crucians*, *A. albimanus*, *A. gambiae*, *A. freeborni*, *A. leucosphyrus*, *A. minimus*, *A. quadrimaculatus*;

Coccoidea, e.g. *Aonidiella aurantia*, *Ferrisia virgate*;

Anthropods of class Arachnida (Mites), e.g. *Pentthaleus major*, *Tetranychus* spp.;

Nematodes, e.g. *Heterodera glycines*, *Meloidogyne* sp., *Pratylenchus* spp., *Caenorhabditis elegans*.

The compounds I are suitable for use in treating or protecting animals against infestation or infection by parasites. Therefore, the invention also relates to the use of a compound of the invention for the manufacture of a medicament for the treatment or protection of animals against infestation or infection by parasites. Furthermore, the invention relates to a method of treating or protecting animals against infestation and infection by parasites, which comprises orally, topically or parenterally administering or applying to the animals a parasitically effective amount of a compound I.

The invention also relates to the non-therapeutic use of compounds of the invention for treating or protecting animals against infestation and infection by parasites. Moreover, the invention relates to a non-therapeutic method of treating or protecting animals against infestation and infection by parasites, which comprises applying to a locus a parasitically effective amount of a compound I.

The compounds of the invention are further suitable for use in combating or controlling parasites in and on animals. Furthermore, the invention relates to a method of combating or controlling parasites in and on animals, which comprises contacting the parasites with a parasitically effective amount of a compound I.

The invention also relates to the non-therapeutic use of compounds I for controlling or combating parasites. Moreover, the invention relates to a non-therapeutic method of combating or controlling parasites, which comprises applying to a locus a parasitically effective amount of a compound I.

The compounds I can be effective through both contact (via soil, glass, wall, bed net, carpet, blankets, or animal parts) and ingestion (e.g. baits). Furthermore, the compounds I can be applied to any and all developmental stages.

The compounds I can be applied as such or in form of compositions comprising them.

5 The term "locus" means the habitat, food supply, breeding ground, area, material or environment in which a parasite is growing or may grow outside of the animal.

As used herein, the term "parasites" includes endo- and ectoparasites. In some embodiments of the invention, endoparasites can be preferred. In other embodiments, ectoparasites can be preferred. Infestations in warm-blooded animals and fish include lice, biting lice, ticks, nasal  
10 bots, keds, biting flies, muscoid flies, flies, myiasitic fly larvae, chiggers, gnats, mosquitoes and fleas.

The compounds of the invention are especially useful for combating the following parasites: *Cimex lectularius*, *Rhipicephalus sanguineus*, and *Ctenocephalides felis*.

As used herein, the term "animal" includes warm-blooded animals (including humans) and fish.  
15 Preferred are mammals, such as cattle, sheep, swine, camels, deer, horses, pigs, poultry, rabbits, goats, dogs and cats, water buffalo, donkeys, fallow deer and reindeer, and also in furbearing animals such as mink, chinchilla and raccoon, birds such as hens, geese, turkeys and ducks and fish such as fresh- and salt-water fish such as trout, carp and eels. Particularly preferred are domestic animals, such as dogs or cats.

20 The compounds I may be applied in total amounts of 0.5 mg/kg to 100 mg/kg per day, preferably 1 mg/kg to 50 mg/kg per day.

For oral administration to warm-blooded animals, the compounds I may be formulated as animal feeds, animal feed premixes, animal feed concentrates, pills, solutions, pastes, suspensions, drenches, gels, tablets, boluses and capsules. For oral administration, the dosage form  
25 chosen should provide the animal with 0.01 mg/kg to 100 mg/kg of animal body weight per day of the compounds I, preferably with 0.5 mg/kg to 100 mg/kg of animal body weight per day.

Alternatively, the compounds I may be administered to animals parenterally, e.g., by intraruminal, intramuscular, intravenous or subcutaneous injection. The compounds I may be dispersed or dissolved in a physiologically acceptable carrier for subcutaneous injection. Alternatively, the  
30 compounds I may be formulated into an implant for subcutaneous administration. In addition, the compounds I may be transdermally administered to animals. For parenteral administration, the dosage form chosen should provide the animal with 0.01 mg/kg to 100 mg/kg of animal body weight per day of the compounds I.

The compounds I may also be applied topically to the animals in the form of dips, dusts, powders, collars, medallions, sprays, shampoos, spot-on and pour-on formulations and in ointments  
35 or oil-in-water or water-in-oil emulsions. For topical application, dips and sprays usually contain 0.5 ppm to 5,000 ppm and preferably 1 ppm to 3,000 ppm of the compounds I. In addition, the

compounds I may be formulated as ear tags for animals, particularly quadrupeds e.g. cattle and sheep.

Oral solutions are administered directly.

Solutions for use on the skin are trickled on, spread on, rubbed in, sprinkled on or sprayed on.

5 Gels are applied to or spread on the skin or introduced into body cavities.

Pour-on formulations are poured or sprayed onto limited areas of the skin, the active compound penetrating the skin and acting systemically. Pour-on formulations are prepared by dissolving, suspending, or emulsifying the active compound in suitable skin-compatible solvents or solvent mixtures.

10 Emulsions can be administered orally, dermally or as injections.

Suspensions can be administered orally or topically/dermally.

Semi-solid preparations can be administered orally or topically/dermally.

For the production of solid preparations, the active compound is mixed with suitable excipients, if appropriate with addition of auxiliaries, and brought into the desired form.

15 The compositions which can be used in the invention can comprise generally from about 0.001 to 95% of the compound I.

Ready-to-use preparations contain the compounds acting against parasites, preferably ectoparasites, in concentrations of 10 ppm to 80% by weight, preferably from 0.1 to 65% by weight, more preferably from 1 to 50% by weight, most preferably from 5 to 40% by weight.

20 Preparations which are diluted before use contain the compounds acting against ectoparasites in concentrations of 0.5 to 90% by weight, preferably of 1 to 50% by weight.

Furthermore, the preparations comprise the compounds of formula I against endoparasites in concentrations of 10 ppm to 2% by weight, preferably of 0.05 to 0.9% by weight, very particularly preferably of 0.005 to 0.25% by weight.

25 Solid formulations which release compounds of the invention may be applied in total amounts of 10 mg/kg to 300 mg/kg, preferably 20 mg/kg to 200 mg/kg, most preferably 25 mg/kg to 160 mg/kg body weight of the treated animal in the course of three weeks.

#### A. Preparation examples

30

The compounds were characterized by melting point determination, by NMR spectroscopy or by the mass-to-charge ratio ( $[m/z]$ ) and retention time (RT; [min.]), as determined by mass spectrometry (MS) coupled with HPLC analysis (HPLC-MS = high performance liquid chromatography-coupled mass spectrometry) or LC analysis (LC-MS = liquid chromatography-coupled mass spectrometry).

35

Method A: HPLC: Shimadzu Nexera UHPLC + Shimadzu LCMS-2020, ESI; Column: Phenomenex Kinetex 1.7 $\mu$ m XB-C18 100A, 2.1x50mm; Mobile phase: A: water + 0.1% TFA; B: ACN;

Temperature: 60°C; Gradient: 5% B to 100% B in 1.5 min; 100% B 0.25 min; Flow: 0.8 mL/min to 1.0 mL/min in 1.51 min; MS: ESI positive; Mass range (m/z): 100–700.

Method B: LC: Shimadzu LC-30AD, ESI; Column: Kinetex EVO C18.5µm 2.1x30mm; Mobile phase: A: water + 0.04% TFA; B: ACN + 0.02% TFA; Temperature: 40°C; Gradient: 5% B to 100% B in 2.5 min; 100% B to 5% B in 0.02min; 5% B for 0.5min; Flow: 0.8mL/min; MS: ESI positive; Mass range: 100–2000.

Method C: HPLC/MS: Agilent 1260 HPLC MSD: 6125B single quadrupole MSD; Column: Luna C18 2.0x50mm 5µm; Mobile phase: A: 0.04% TFA in water; B: 0.02% TFA in ACN; Temperature: 40°C; Gradient: 5% B for 0.4min; 5% B to 95% B in 2.6 min; 95% B for 1 min; 95% B to 5% B in 0.01min; 5% B for 0.5min; Flow: 1.0mL/min; MS: ES-API positive; Mass range: 100–1000.

Example 1: Preparation of 3-bromo-N-[1-[3-[1-(2,2,2-trifluoroethyl)-1,2,4-triazol-3-yl]pyrazin-2-yl]ethyl]-5-(trifluoromethyl)benzamide [I1-1]

Step 1: Synthesis of (N)-3-chloro-N-(dimethylaminomethylene)pyrazine-2-carboxamide

To a solution of 3-chloropyrazine-2-carboxamide (3g, 0.0191mol) in DCM (30mL) was added DMF-dimethyl acetal (4.5g, 0.0382mol) at 20°C. The mixture was stirred at 50°C for 2h, LCMS showed the reaction was completed. The reaction mixture was concentrated to give the title compound (3g, yield: crude) as a white solid, which was used for the next step directly.

Step 2: Synthesis of 2-chloro-3-(1H-1,2,4-triazol-3-yl)pyrazine

To a solution of (N)-3-chloro-N-(dimethylaminomethylene)pyrazine-2-carboxamide (3g, 0.0141mol) in 1,4-dioxane (30mL) was added  $\text{NH}_2\text{NH}_2 \cdot \text{H}_2\text{O}$  (1.4g, 0.0283mol) and AcOH (30mL) at 20°C. The mixture was stirred at 80°C for 2h, LCMS showed the reaction was completed. The reaction mixture was concentrated to give crude 2-chloro-3-(1H-1,2,4-triazol-3-yl)pyrazine (3g, crude) as a yellow solid, which was directly used for the next step. A small portion was crystallized for characterization.

$^1\text{H-NMR}$  (400MHz, DMSO- $d_6$ ):  $\delta$  = 8.64 (m, 2H), 8.80 (d, 1H).

Step 3: Synthesis of 2-chloro-3-[1-(2,2,2-trifluoroethyl)-1,2,4-triazol-3-yl]pyrazine

To a mixture of 2-chloro-3-(1H-1,2,4-triazol-3-yl)pyrazine (1.6g, 0.0088mol) in MeCN (80mL) was added 2,2,2-trifluoroethyl trifluoromethanesulfonate (2.45g, 0.0106mol) and  $\text{K}_2\text{CO}_3$  (2.276g, 0.0176mol) at 20°C. The reaction mixture was stirred at 25°C for 12h. LCMS showed 70% of the product. The reaction mixture was quenched with  $\text{H}_2\text{O}$  (20mL), extracted with EtOAc (3x80mL), the separated organic layers were washed with brine (20mL), dried over  $\text{Na}_2\text{SO}_4$  and concentrated. The residue was purified by silica gel column (PE: EtOAc = 100:0 gradient to 20:80) to give 2-chloro-3-[1-(2,2,2-trifluoroethyl)-1,2,4-triazol-3-yl]pyrazine (0.600 g, yield: 26%).

$^1\text{H NMR}$  (400MHz,  $\text{CDCl}_3$ ):  $\delta$  = 5.24 (q, 2H), 8.17 (s, 1H), 8.57 (d, 1H), 8.64 (d, 1H).

Step 4: Synthesis of 2-(1-ethoxyvinyl)-3-[1-(2,2,2-trifluoroethyl)-1,2,4-triazol-3-yl]pyrazine

To a solution of 2-chloro-3-[1-(2,2,2-trifluoroethyl)-1,2,4-triazol-3-yl]pyrazine (3.8g, 0.0144mol) in toluene (100mL) was added tributyl(1-ethoxyvinyl)stannane (5.21g, 0.0144mol) and

Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> (1g) at 25°C. The reaction mixture was stirred for 12h at 110°C. LCMS showed the reaction was completed. After the reaction mixture was cooled down to room temperature, saturated aqueous KF (150mL) was added to the reaction mixture and stirred for another 30min. The mixture was filtered through a celite pad and the filtrate was extracted with EtOAc (3x50mL). The separated organic phase was washed with brine (60mL), dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The residue was purified by silica gel column (PE: EtOAc = 100:0 gradient to 10:90) to give the title compound (3.1g, yield: 72%).

<sup>1</sup>H NMR (400MHz, CDCl<sub>3</sub>): δ = 1.01 (t, 3H), 3.78 (q, 2H), 4.49 (d, 1H), 4.84-4.88 (m, 1H), 4.89-4.94 (m, 2H), 8.30 (s, 1H), 8.61 (m, 2H).

10 Step 5: Synthesis of 1-[3-[1-(2,2,2-trifluoroethyl)-1,2,4-triazol-3-yl]pyrazin-2-yl]ethanone

To a solution of 2-(1-ethoxyvinyl)-3-[1-(2,2,2-trifluoroethyl)-1,2,4-triazol-3-yl]pyrazine (3.1g, 0.0103mol) in THF (30mL) was added aqueous HCl (2M, 30mL) dropwise at 25°C. The mixture was stirred for 16h at 25°C. LCMS showed the reaction was completed. The reaction mixture was diluted with H<sub>2</sub>O (50mL), extracted with EtOAc (3x20 mL). The separated organic phase 15 was washed with brine (40mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give the title compound (2.9g, crude).

<sup>1</sup>H-NMR (400MHz, CDCl<sub>3</sub>): δ = 2.70 (s, 3H), 4.97 (q, 2H), 8.69 (s, 2H), 8.80 (br s, 1H).

Step 6: Synthesis of 1-[3-[1-(2,2,2-trifluoroethyl)-1,2,4-triazol-3-yl]pyrazin-2-yl]ethanamine

To a solution of 1-[3-[1-(2,2,2-trifluoroethyl)-1,2,4-triazol-3-yl]pyrazin-2-yl]ethanone (1.3g, 4.79mmol) in MeOH (50mL) was added NH<sub>4</sub>OAc (3.69g, 48mmol), NaBH<sub>3</sub>CN (602mg, 9.59mmol) and the reaction mixture was stirred for 16h at 20°C. TLC (DCM:MeOH = 10:1) showed the reaction was completed. The reaction mixture was concentrated and quenched with H<sub>2</sub>O (50mL), the pH was adjusted to pH~10 with aq. NaOH. The mixture was extracted with DCM/iPrOH (3/1, 3x20mL), the combined organic phases were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated to give crude 1-[3-[1-(2,2,2-trifluoroethyl)-1,2,4-triazol-3-yl]pyrazin-2-yl]ethanamine 25 (500mg, crude), which was used in the next step without further purification.

Step 7: Synthesis of 3-bromo-N-[1-[3-[1-(2,2,2-trifluoroethyl)-1,2,4-triazol-3-yl]pyrazin-2-yl]ethyl]-5-(trifluoromethyl)benzamide

To a solution of 3-bromo-5-(trifluoromethyl)benzoic acid (0.494g, 0.00184mol) in MeCN 30 (10mL) was added N,N,N',N'-tetramethylchloroformamidinium hexafluorophosphate (0.773g, 0.00276mol), N-methylimidazole (0.453g, 0.0055mol) and 1-[3-[1-(2,2,2-trifluoroethyl)-1,2,4-triazol-3-yl]pyrazin-2-yl]ethanamine (0.5g, 0.00184mol) at 20°C. The mixture was stirred at 20°C for 1h. LCMS showed the reaction was completed. The reaction mixture was quenched with H<sub>2</sub>O (10mL), extracted with EtOAc (3x30mL): The combined organic layers were washed with brine 35 (10mL), dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The residue was purified by Prep-HPLC (NH<sub>4</sub>HCO<sub>3</sub>) to give the title compound (I1-1, 0.375g, yield: 39%) as a white solid.

<sup>1</sup>H-NMR (400MHz, CDCl<sub>3</sub>): δ = 1.63 (d, 3H), 4.98 (m, 2H), 5.23 (quin, 1H), 7.84 (br d, 1H), 7.90 (s, 1H), 8.02 (s, 1H), 8.15 (s, 1H), 8.43 (s, 1H), 8.67 (d, 1H), 8.74 (d, 1H).

LCMS (Method B): (Desired Mass: m/z = 523; Observed Mass: m/z = 523.525).

5 Example 2: Preparation of 2,6-dichloro-N-[1-[3-(1-phenyl-1,2,4-triazol-3-yl)pyrazin-2-yl]ethyl]pyridine-4-carboxamide [I2-1]

Step 1: Preparation of 2-chloro-3-[1-[(4-methoxyphenyl)methyl]-1,2,4-triazol-3-yl]pyrazine

To a solution of 3-chloro-N-(dimethylaminomethylene)pyrazine-2-carboxamide (84g, 376.2mmol) in 1,4-dioxan (840ml) was added [(4-methoxyphenyl)methylamino]ammonium chloride (142g, 752.4mmol) at 15°C and stirred for 30min. Acetic acid (840mL) was added and the mixture was stirred at 15°C for further 2h. Then the reaction mixture was heated to 80°C and stirred for 16h. LC-MS showed the reaction was completed. The reaction was quenched with water (600mL). The resulting mixture was extracted with EtOAc (3x1L). The combined organic phase was washed with brine (300mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced pressure. The residue was purified by column (EtOAc) to give a mixture of 2-chloro-3-[1-[(4-methoxyphenyl)methyl]-1,2,4-triazol-3-yl]pyrazine and 2-chloro-3-[2-[(4-methoxyphenyl)methyl]-1,2,4-triazol-3-yl]pyrazine (66g crude) as a yellow oil.

<sup>1</sup>H-NMR (400MHz, CDCl<sub>3</sub>): δ = 8.62 (d, J=2.38Hz, 1H), 8.48 (d, J=2.38Hz, 1H), 8.08 (s, 1H), 7.06 (d, J=8.66Hz, 2H), 6.75-6.80 (m, 2H), 5.45 (s, 2H), 3.75 (s, 3H).

20 Step 2: Preparation of 1-[3-[1-[(4-methoxyphenyl)methyl]-1,2,4-triazol-3-yl]pyrazin-2-yl]ethanone: To a solution of a mixture of 2-chloro-3-[1-[(4-methoxyphenyl)methyl]-1,2,4-triazol-3-yl]pyrazine and 2-chloro-3-[2-[(4-methoxyphenyl)methyl]-1,2,4-triazol-3-yl]pyrazine (66g, 218.7mmol) in DMF was added Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> (15.3g, 21.87mmol) and tributyl(1-ethoxyvinyl)stannane (18.5g, 328.1mmol) at 15°C. The reaction mixture was heated to 100°C and stirred for 16h. TCL (EtOAc) showed that the reaction was completed. The reaction mixture was poured into KF (aq. sat, 1L) and stirred for 2.5h. The mixture was filtered and the filtrate was extracted with EtOAc (3x1L). The combined organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced pressure. The residue was purified by column (EtOAc) to give a mixture of 1-[3-[1-[(4-methoxyphenyl)methyl]-1,2,4-triazol-3-yl]pyrazin-2-yl]ethanone and 1-[3-[2-[(4-methoxyphenyl)methyl]-1,2,4-triazol-3-yl]pyrazin-2-yl]ethanone (57g crude) as a yellow solid.

<sup>1</sup>H-NMR (400MHz, CDCl<sub>3</sub>): δ = 8.75 (d, J=2.38, 1H), 8.66 (d, J=2.50Hz, 1H), 7.96 (s, 1H), 7.18-7.24 (m, 2H), 6.78-6.86 (m, 2H), 5.60 (s, 2H), 3.77 (s, 3H), 2.72 (s, 3H).

35 Step 3: Preparation of 1-[3-(1H-1,2,4-triazol-3-yl)pyrazin-2-yl]ethanone: A solution of 1-[3-[1-[(4-methoxyphenyl)methyl]-1,2,4-triazol-3-yl]pyrazin-2-yl]ethanone and 1-[3-[2-[(4-methoxyphenyl)methyl]-1,2,4-triazol-3-yl]pyrazin-2-yl]ethanone (5.7g, 18.43mmol) in TFA (57ml) was stirred at 80°C for 16h. LC-MS showed the reaction was completed. The mixture was

concentrated under reduced pressure and purified by column (EtOAc:EtOH=3:1) to give 1-[3-(1*H*-1,2,4-triazol-3-yl)pyrazin-2-yl]ethanone (3.4g, crude) as a light yellow solid.

<sup>1</sup>H-NMR (400MHz, CDCl<sub>3</sub>): δ = 8.81 (d, J=2.50Hz, 1H), 8.71 (d, J=2.50Hz, 1H), 8.46 (br s, 1H), 2.69 (s, 3H).

5 Step 4: Preparation of 1-[3-[1-(4-nitrophenyl)-1,2,4-triazol-3-yl]pyrazin-2-yl]ethanone: To a solution of 1-[3-(1*H*-1,2,4-triazol-3-yl)pyrazin-2-yl]ethanone (3g, 15.86mmol) in DMF was added NaH (571mg, 23.79mmol) at 0°C. A solution of 1-fluoro-4-nitro-benzene (2.91g, 20.62mmol) in DMF (10mL) was added. The reaction mixture was stirred at 15°C for 16h. TLC (EtOAc:EtOH=3:1) showed the reaction was completed. The mixture was quenched with water (120mL) and extracted with EtOAc (3x80mL). The combined organic phase was washed with brine (3x80ml), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced pressure. The residue was purified by column (EtOAc:EtOH=3:1) to give 1-[3-[1-(4-nitrophenyl)-1,2,4-triazol-3-yl]pyrazin-2-yl]ethanone (4.5g, 91.5% yield) as a yellow solid.

10 <sup>1</sup>H-NMR (400MHz, CDCl<sub>3</sub>): δ = 8.83 (d, J=2.38Hz, 1H), 8.79 (s, 1H), 8.69 (d, J=2.38Hz, 1H), 8.40-8.45 (m, 2H), 7.96-8.00 (m, 2H), 2.80 (s, 3H).

Step 5: Preparation of 1-[3-[1-(4-aminophenyl)-1,2,4-triazol-3-yl]pyrazin-2-yl]ethanone: To a solution of 1-[3-[1-(4-nitrophenyl)-1,2,4-triazol-3-yl]pyrazin-2-yl]ethanone (4.4g, 14.18mmol) in MeOH (45ml) was added SnCl<sub>2</sub> (8.067g, 42.54mmol) at 15°C. The reaction mixture was heated to 80°C and stirred for 3h. LC-MS showed the reaction was completed. The mixture was concentrated and then quenched with water (20ml). The pH was adjusted to pH~9 with NaOH (aq. 2N) and then extracted with EtOAc (3x20mL). The combined organic phase was washed with brine (20mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced pressure. The residue was purified by column (EtOAc:EtOH=3:1) to give 1-[3-[1-(4-aminophenyl)-1,2,4-triazol-3-yl]pyrazin-2-yl]ethanone (750mg, 19% yield) as a yellow solid.

25 <sup>1</sup>H-NMR (400MHz, DMSO-*d*<sub>6</sub>): δ = 9.15 (s, 1H), 8.89 (d, J=2.50Hz, 1H), 8.76 (d, J=2.50Hz, 1H), 7.46-7.54 (m, 2H), 6.66-6.72 (m, 2H), 5.49 (s, 2H), 2.64 (s, 3H).

Step 6: Preparation of 1-[3-(1-phenyl-1,2,4-triazol-3-yl)pyrazin-2-yl]ethanone: To a solution of 1-[3-[1-(4-aminophenyl)-1,2,4-triazol-3-yl]pyrazin-2-yl]ethanone (720mg, 2.57mmol) in DMF (8mL) was added NaNO<sub>2</sub> (355mg, 5.14mmol) and Et<sub>2</sub>O·BF<sub>3</sub> (725mg, 5.14mmol) at 15°C. The reaction mixture was heated to 50°C and stirred for 16h. LC-MS showed reaction was completed. The mixture was quenched with water (30mL) and extracted with EtOAc (3x20mL). The combined organic phase was washed with brine (3x20mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced pressure. The residue was purified by column (EtOAc) to give 1-[3-(1-phenyl-1,2,4-triazol-3-yl)pyrazin-2-yl]ethanone (480mg, 70% yield) as a yellow solid.

35 <sup>1</sup>H-NMR (400MHz, MeOH-*d*<sub>4</sub>): δ = 9.18 (s, 1H), 8.84 (d, J=2.26Hz, 1H), 8.74 (d, J=2.26Hz, 1H), 7.86 (d, J=8.16Hz, 2H), 7.58 (t, J=7.78Hz, 2H), 7.44-7.50 (m, 1H), 2.74 (s, 3H).

Step 7: Preparation of 1-[3-(1-phenyl-1,2,4-triazol-3-yl)pyrazin-2-yl]ethanamine: To a solution of 1-[3-(1-phenyl-1,2,4-triazol-3-yl)pyrazin-2-yl]ethanone (450mg, 1.70mmol) in MeOH (30mL) was added NH<sub>3</sub> in MeOH (7M, 6mL) and NH<sub>4</sub>OAc (1.308g, 17.0mmol) at 15°C. The reaction mixture was stirred for 3h. Then the mixture was heated to 50°C and stirred for 16h. LC-MS showed the reaction was completed. The mixture was quenched with water (90mL) and extracted with EtOAc (3x50mL). The combined organic phase was washed with brine (50mL) dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced pressure to give 1-[3-(1-phenyl-1,2,4-triazol-3-yl)pyrazin-2-yl]ethanamine (400mg, crude) as a yellow solid.

<sup>1</sup>H-NMR (400MHz, DMSO-*d*<sub>6</sub>): δ = 9.51 (s, 1H), 8.73-8.79 (m, 1H), 8.68 (d, J=2.25Hz, 1H), 7.94-7.98 (m, 2H), 7.62 (t, J=7.94Hz, 2H), 7.47 (t, J=7.38Hz, 1H), 4.77 (q, J=6.63Hz, 1H), 3.10-3.47 (m, 2H), 1.38 (d, J=6.63Hz, 3H).

Step 8: Preparation of 2,6-dichloro-*N*-[1-[3-(1-phenyl-1,2,4-triazol-3-yl)pyrazin-2-yl]ethyl]pyridine-4-carboxamide [I2-1]: To a solution of 1-[3-(1-phenyl-1,2,4-triazol-3-yl)pyrazin-2-yl]ethanamine (433mg, 2.53mmol) in ACN (4mL) was added NMI (370mg, 4.506mmol) and TCFH (631mg, 2.253mmol) at 15°C. A solution of 2,6-dichloropyridine-4-carboxylic acid (400mg, 1.502mmol) in ACN (4mL) was added. The mixture was stirred at 15°C for 16h. LC-MS showed the reaction was completed. The mixture was concentrated under reduced pressure and purified by prep-HPLC (NH<sub>4</sub>HCO<sub>3</sub>) to give 2,6-dichloro-*N*-[1-[3-(1-phenyl-1,2,4-triazol-3-yl)pyrazin-2-yl]ethyl]pyridine-4-carboxamide (I2-1, 102mg, 15% yield) as a yellow solid.

<sup>1</sup>H-NMR (400MHz, CDCl<sub>3</sub>): δ = 8.74-8.81 (m, 2H), 8.67 (d, J=2.26Hz, 1H), 7.99 (br d, J=7.65Hz, 1H), 7.82 (d, J=7.65Hz, 2H), 7.65 (s, 2H), 7.59 (t, J=7.84Hz, 2H), 7.45-7.51 (m, 1H), 6.54-6.64 (m, 1H), 1.68 (d, J=6.53Hz, 3H).

Example 3: Preparation of 3-chloro-*N*-[1-[3-[1-[(4-methoxyphenyl)methyl]-1,2,4-triazol-3-yl]pyrazin-2-yl]ethyl]-5-(trifluoromethyl)benzamide [I1-4]

Step 1: Preparation of 1-[3-[1-[(4-methoxyphenyl)methyl]-1,2,4-triazol-3-yl]pyrazin-2-yl]ethanamine

To a solution of 1-[3-[1-[(4-methoxyphenyl)methyl]-1,2,4-triazol-3-yl]pyrazin-2-yl]ethanone and 1-[3-[2-[(4-methoxyphenyl)methyl]-1,2,4-triazol-3-yl]pyrazin-2-yl]ethanone (10g, 32.4mmol) in MeOH (1L) was added NH<sub>3</sub> in MeOH (7M, 100mL) and NH<sub>4</sub>OAc (25g, 324mmol) at 15°C. The reaction mixture was stirred for 30min. Then the mixture was heated to 50°C and stirred for 16h. LC-MS showed the reaction was completed. The reaction mixture was concentrated under reduced pressure and purified by HPLC to give a mixture of 1-[3-[1-[(4-methoxyphenyl)methyl]-1,2,4-triazol-3-yl]pyrazin-2-yl]ethanamine and 1-[3-[2-[(4-methoxyphenyl)methyl]-1,2,4-triazol-3-yl]pyrazin-2-yl]ethanamine (10g, 50% yield) as a yellow oil.

Step 2: Preparation of 3-chloro-*N*-[1-[3-[1-[(4-methoxyphenyl)methyl]-1,2,4-triazol-3-yl]pyrazin-2-yl]ethyl]-5-(trifluoromethyl)benzamide (I1-4)

To a solution of 3-chloro-5-(trifluoromethyl)benzoic acid (10.8g, 48.3mmol) in DMF (50mL) was added TEA (6.5g, 64.4mmol) and HATU (18.4g, 48.4mmol) at 0°C under N<sub>2</sub>-atmosphere. The reaction mixture was stirred for 30min at this temperature. A mixture of 1-[3-[1-[(4-methoxyphenyl)methyl]-1,2,4-triazol-3-yl]pyrazin-2-yl]ethanamine and 1-[3-[2-[(4-methoxyphenyl)methyl]-1,2,4-triazol-3-yl]pyrazin-2-yl]ethanamine (8g, 32.2mmol) in DMF (10mL) was added to the reaction mixture and stirred at 15°C for 16h. TLC (EtOAc:EtOH=3:1) showed the reaction was completed. The reaction was quenched with NH<sub>4</sub>Cl (aq., 50mL) and extracted with EtOAc (3x50mL). The combined organic phase was washed with brine (3x50mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced pressure. The residue was purified by column (EtOAc:EtOH=3:1) to give 3-chloro-*N*-[1-[3-[1-[(4-methoxyphenyl)methyl]-1,2,4-triazol-3-yl]pyrazin-2-yl]ethyl]-5-(trifluoromethyl)benzamide (11-4, 3g, 18.1% yield) as a yellow oil.

<sup>1</sup>H-NMR (400MHz, CDCl<sub>3</sub>): δ = 8.71 (d, J=2.38 Hz, 1H), 8.62 (d, J=2.38 Hz, 1H), 8.14 (s, 1H), 7.96-8.04 (m, 3H), 7.74 (s, 1H), 7.35 (d, J=8.66 Hz, 2H), 6.94 (d, J=8.66 Hz, 2H), 6.47-6.57 (m, 1H), 5.43 (s, 2H), 3.83 (s, 3H), 1.60 (d, J=6.65 Hz, 3H).

Example 4: Preparation of 3-chloro-*N*-[1-[3-[1-[(2,2-dichlorocyclopropyl)methyl]-1,2,4-triazol-3-yl]pyrazin-2-yl]ethyl]-5-(trifluoromethyl)benzamide [I1-14]

Step 1: Preparation of 3-chloro-*N*-[1-[3-(1*H*-1,2,4-triazol-3-yl)pyrazin-2-yl]ethyl]-5-(trifluoromethyl)benzamide [INT]

A solution of a mixture of 3-chloro-*N*-[1-[3-[1-[(4-methoxyphenyl)methyl]-1,2,4-triazol-3-yl]pyrazin-2-yl]ethyl]-5-(trifluoromethyl)benzamide and 3-chloro-*N*-[1-[3-[2-[(4-methoxyphenyl)methyl]-1,2,4-triazol-3-yl]pyrazin-2-yl]ethyl]-5-(trifluoromethyl)benzamide (11g, 21.3mmol) in TFA (10mL) was heated to 80°C and stirred for 16h. LC-MS showed the reaction was completed. The reaction mixture was concentrated under reduced pressure and purified by column (EtOAc:EtOH=3:1) to give 3-chloro-*N*-[1-[3-(1*H*-1,2,4-triazol-3-yl)pyrazin-2-yl]ethyl]-5-(trifluoromethyl)benzamide (6g, 71.4% yield) as a gray solid.

<sup>1</sup>H-NMR (400MHz, CDCl<sub>3</sub>): δ = 8.69 (d, J=2.25Hz, 1H), 8.65 (d, J=2.25Hz, 1H), 8.37 (s, 1H), 8.25 (br dd, J=7.00, 1.88Hz, 1H), 8.03 (s, 1H), 7.99 (s, 1H), 7.75 (s, 1H), 6.51-6.61 (m, 1H) 1.68 (d, J=6.75Hz, 3H).

LCMS (Method B): (Desired Mass: m/z = 396.0; Observed Mass: m/z = 397.0)

Step 2: Preparation of 3-chloro-*N*-[1-[3-[1-[(2,2-dichlorocyclopropyl)methyl]-1,2,4-triazol-3-yl]pyrazin-2-yl]ethyl]-5-(trifluoromethyl)benzamide [I1-14]

To a solution of 3-chloro-*N*-[1-[3-(1*H*-1,2,4-triazol-3-yl)pyrazin-2-yl]ethyl]-5-(trifluoromethyl)benzamide (500mg, 1.26mmol) in toluene (10mL) was added (2,2-dichlorocyclopropyl)methanol (354mg, 2.5mmol) and (tributylphosphoranylidene)acetonitrile (600mg, 2.5mmol) at 20°C. The reaction mixture was heated to 130°C and stirred for 12h. LC-MS showed the reaction was completed. The mixture was concentrated under reduced pressure and purified by

prep-HPLC (TFA) to give 3-chloro-*N*-[1-[3-[1-[(2,2-dichlorocyclopropyl)methyl]-1,2,4-triazol-3-yl]pyrazin-2-yl]ethyl]-5-(trifluoromethyl)benzamide (I1-14, 80mg, 12% yield) as a yellow syrup.

<sup>1</sup>H-NMR (400MHz, CHCl<sub>3</sub>-d): δ = 8.72 (d, 1H), 8.71 (d, 1H), 8.50 (s, 1H), 8.01-7.96 (m, 3H), 7.72 (s, 1H), 6.54-6.51 (M, 1H), 4.63-4.57 (m, 1H), 4.52-4.46 (m, 1H), 2.34-2.2.30 (m, 1H), 1.89-  
5 1.87 (m, 1H), 1.63 (d, 3H), ,1.54-1.49 (m, 1H).

Example 5: Preparation of 3-chloro-*N*-[1-[3-[1-(3,3-dichloroallyl)-1,2,4-triazol-3-yl]pyrazin-2-yl]ethyl]-5-(trifluoromethyl)benzamide [I1-11]

To a solution of 3-chloro-*N*-[1-[3-(1*H*-1,2,4-triazol-3-yl)pyrazin-2-yl]ethyl]-5-(trifluoromethyl)benzamide (1g, 2.52mmol) in ACN (20mL) was added 1,1,3-trichloroprop-1-ene (367mg, 5.04mmol) and K<sub>2</sub>CO<sub>3</sub> (696mg, 5.04mmol) at 20°C. The reaction mixture was heated to 50°C and stirred for 12h. LC-MS showed the reaction was completed. The reaction was quenched with water (20mL) and extracted with EtOAc (3x8mL). The combined organic phase was washed with brine (4x20mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced pressure. The residue was purified by prep-HPLC (TFA) to give 3-chloro-*N*-[1-[3-[1-(3,3-dichloroallyl)-1,2,4-triazol-3-yl]pyrazin-2-yl]ethyl]-5-(trifluoromethyl)benzamide (I1-11, 200mg, 16% yield) as a yellow solid.

<sup>1</sup>H-NMR (400MHz, MeOH-*d*<sub>4</sub>): δ = 8.66-8.70 (m, 2H), 8.63 (d, J=2.13Hz, 1H), 8.10 (s, 1H), 8.07 (s, 1H), 7.87 (s, 1H), 6.43 (t, J=6.9Hz, 1H), 6.25 (q, J=6.88Hz, 1H), 5.14 (d, H=6.9Hz, 2H),  
20 1.68 (d, J=6.88Hz, 3H).

Example 6: Preparation of 3-chloro-*N*-[1-[3-(1-isopropyl-1,2,4-triazol-3-yl)pyrazin-2-yl]ethyl]-*N*-methyl-5-methylsulfonyl-benzamide [I1-5]

To a solution of 3-chloro-*N*-[1-[3-(1-isopropyl-1,2,4-triazol-3-yl)pyrazin-2-yl]ethyl]-5-methylsulfonyl-benzamide (I1-7, 300mg, 0.67mmol) in DMF (5mL) was added NaH (24mg, 1mmol) portionwise at 0°C. The reaction mixture was stirred for 30min. MeI (73mg, 0.52mmol) was added and the mixture was stirred for 16h at 15°C. TLC (EtOAc:EtOH=3:1) showed the reaction was completed. The reaction was quenched with water (15mL) and extracted with EtOAc (3x10mL). The combined organic phase was washed with brine (3x10mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced pressure. The residue was purified by prep-HPLC (NH<sub>4</sub>HCO<sub>3</sub>) to give 3-chloro-*N*-[1-[3-(1-isopropyl-1,2,4-triazol-3-yl)pyrazin-2-yl]ethyl]-*N*-methyl-5-methylsulfonyl-benzamide (I1-5, 280mg, 90% yield) as a white solid.

<sup>1</sup>H-NMR (400MHz, DMSO-*d*<sub>6</sub>): δ = 8.70 (d, J=2.32Hz, 1H), 8.67 (d, J=2.20Hz, 1H), 8.54 (br s, 1H), 7.91 (br s, 1H), 7.55 (br s, 2H), 5.99-6.31 (m, 1H), 4.63 (sept, J=6.7Hz 1H), 3.22 (s, 3H),  
35 2.87-3.04 (m, 3H), 1.62 (d, J=6.97Hz, 3H), 1.48 (d, J=6.72Hz, 6H).

With appropriate modification of the starting materials, the procedures given in the synthesis descriptions were used to obtain further compounds I. The compounds obtained in this manner are listed in the tables that follow, together with physical data.






Table I2 – compounds of formula I.2

No.	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	Method	phys. data (HPLC RT [min])	M+H [m/z]
I2-1	H	CH <sub>3</sub>	3-Cl, 5-Cl	C <sub>6</sub> H <sub>5</sub>	B	1.61	440.2

## Biological examples

If not otherwise specified, the test solutions were prepared as follow:

The active compound was dissolved at the desired concentration in a mixture of 1:1 (vol:vol) distilled water : acetone. The test solution was prepared on the day of use.

5 The activity of the compounds of formula I of the present invention can be demonstrated and evaluated by the following biological tests.

### B.1 Green Peach Aphid (*Myzus persicae*)

For evaluating control of green peach aphid (*Myzus persicae*) through systemic means, the test unit consisted of 96-well-microtiter plates containing liquid artificial diet under an artificial  
10 mem brane.

The compounds were formulated using a solution containing 75% v/v water and 25% v/v DMSO. Different concentrations of formulated compounds were pipetted into the aphid diet, using a custom built pipetter, at two replications.

After application, 5 - 8 adult aphids were placed on the artificial membrane inside the microtiter  
15 plate wells. The aphids were then allowed to suck on the treated aphid diet and incubated at about  $23 \pm 1^\circ\text{C}$  and about  $50 \pm 5\%$  relative humidity for 3 days. Aphid mortality and fecundity was then visually assessed.

In this test, compounds I1-1, I1-2, I1-3, I1-5, I1-6, I1-7, I1-8, I1-9, I1-10, I1-12, I1-13, I1-14, I-  
20 15, and I2-1, resp., at 2500 ppm showed at least 75% mortality in comparison with untreated controls.

### B.2 Tobacco budworm (*Heliothis virescens*)

For evaluating control of tobacco budworm (*Heliothis virescens*), the test unit consisted of 96-well-microtiter plates containing an insect diet and 15-25 *H. virescens* eggs.

25 The compounds were formulated using a solution containing 75% v/v water and 25% v/v DMSO. Different concentrations of formulated compounds were sprayed onto the insect diet at 10  $\mu\text{l}$ , using a custom-built micro atomizer, at two replications.

After application, microtiter plates were incubated at about  $28 \pm 1^\circ\text{C}$  and about  $80 \pm 5\%$  relative humidity for 5 days. Egg and larval mortality was then visually assessed.

30 In this test, compounds I1-1, I1-2, I1-3, I1-8, I1-9, I1-11, I1-12, I1-13, and I1-14, resp., at 2500 ppm showed at least 75% mortality in comparison with untreated controls.

### B.3 Boll weevil (*Anthonomus grandis*)

For evaluating control of boll weevil (*Anthonomus grandis*), the test unit consisted of 96-well-  
35 microtiter plates containing an insect diet and 5-10 *A. grandis* eggs.

The compounds were formulated using a solution containing 75% v/v water and 25% v/v DMSO. Different concentrations of formulated compounds were sprayed onto the insect diet at 5 µl, using a custom-built micro atomizer, at two replications.

After application, microtiter plates were incubated at about  $25 \pm 1^\circ\text{C}$  and about  $75 \pm 5\%$  relative humidity for 5 days. Egg and larval mortality was then visually assessed.

In this test, compounds I1-1, I1-2, I1-3, I1-4, I1-5, I1-6, I1-7, I1-8, I1-9, I1-10, I1-11, I1-12, I1-13, I1-14, I1-15, and I2-1, resp., at 2500 ppm showed at least 75% mortality in comparison with untreated controls.

#### 10 B.4. Southern armyworm (*Spodoptera eridania*), 2nd instar larvae

The active compounds were formulated by a Tecan liquid handler in 100% cyclohexanone as a 10,000-ppm solution supplied in tubes. The 10,000-ppm solution was serially diluted in 100% cyclohexanone to make interim solutions. These served as stock solutions for which final dilutions were made by the Tecan in 50% acetone:50% water (v/v) into 10 or 20ml glass vials. A non-ionic surfactant (Kinetic®) was included in the solution at a volume of 0.01% (v/v). The vials were then inserted into an automated electrostatic sprayer equipped with an atomizing nozzle for application to plants/insects. Lima bean plants (variety Sieva) were grown 2 plants to a pot and selected for treatment at the 1st true leaf stage. Test solutions were sprayed onto the foliage by an automated electrostatic plant sprayer equipped with an atomizing spray nozzle. The plants were dried in the sprayer fume hood and then removed from the sprayer. Each pot was placed into perforated plastic bags with a zip closure. Ten to 11 armyworm larvae were placed into the bag and the bags zipped closed. Test plants were maintained in a growth room at about  $25^\circ\text{C}$  and about 20-40% relative humidity for 4 days, avoiding direct exposure to fluorescent light (14:10 light:dark photoperiod) to prevent trapping of heat inside the bags. Mortality and reduced feeding were assessed 4 days after treatment, compared to untreated control plants.

In this test, compounds I1-1, I1-2, I1-3, I1-4, I1-5, I1-6, I1-7, I1-8, I1-10, I1-12, I1-13, and I1-14, resp., at 300 ppm at least 75 % mortality in comparison with untreated controls.

#### B.5 Yellow fever mosquito (*Aedes aegypti*)

30 For evaluating control of yellow fever mosquito (*Aedes aegypti*) the test unit consisted of 96-well-microtiter plates containing 200µl of tap water per well and 5-15 freshly hatched *A. aegypti* larvae.

The active compounds were formulated using a solution containing 75% (v/v) water and 25% (v/v) DMSO. Different concentrations of formulated compounds or mixtures were sprayed onto the insect diet at 2.5µl, using a custom-built micro atomizer, at two replications.

After application, microtiter plates were incubated at  $28 \pm 1^\circ\text{C}$ ,  $80 \pm 5\%$  RH for 2 days. Larval mortality was then visually assessed.

In this test, compounds I1-1, I1-2, I1-3, I1-5, I1-6, I1-7, I1-8, I1-9, I1-10, I1-11, I1-12, I1-13, I1-14, I1-15, and I2-1, resp., at 2500 ppm showed at least 75% mortality in comparison with untreated controls.

- 5 The beneficial activity of the compounds according to the invention with a C-bonded triazole over structurally close compounds known from prior art with N-bonded triazoles was demonstrated by the following comparative experiments:

B.6 ANAPCO (Orchid thrips; *Dichromothrips corbetti*)

- 10 *Dichromothrips corbetti* adults used for bioassay are obtained from a colony maintained continuously under laboratory conditions. For testing purposes, the test compound is diluted in a 1:1 mixture of acetone:water (vol:vol), plus Kinetic at a rate of 0.01% v/v.



- Thrips potency of each compound is evaluated by using a floral-immersion technique. Each orchid petal is dipped into treatment solution and allowed to dry in Petri dishes. Treated petals  
15 are placed into individual re-sealable plastic along with about 20 adult thrips. All test arenas are held under dark condition and a temperature of about 28°C for duration of the assay. The percent mortality is recorded 72 hours after treatment.



B.7 APHICR (Black bean aphid; *Aphis craccivora*)



- 20 The active compound is dissolved at the desired concentration in a mixture of 1:1 (vol:vol) distilled water : acetone. Surfactant (Kinetic) is added at a rate of 0.01% (vol/vol). The test solution is prepared at the day of use.

- Potted (Kord traditional square pots Size 3" and 2.5" in depth) bush beans are cleaned with the apical leaves removed using pointed forceps, leaving only the cotyledon leaves. Plants are  
25 inoculated with about 30 mixed-stage aphid colony 24 hours before spraying. Potted bean plants are sprayed with the test solutions using a DeVilbiss hand atomizer (20-30 psi). Treated plants are allowed to air-dry in the laboratory for about an hour before placing them inside the holding room maintained at 27°C, 50% RH and 72 hours light conditions. Stem of the treated bean plants are inserted in the slit of cut circle filter paper to catch the falling dead aphids. As-  
30 sessment of population reduction (% mortality) is done after 72 hours.

The tables show % mortality in comparison to untreated controls.


Structure	Example	B.1 9.9 ppm	B.6 300 ppm	B.7 300 ppm
	I1-12	100%	100%	100%
	WO 2021/037614 P1	0%	0%	0%

Structure	Example	B.1 9.9 ppm	B.6 300 ppm	B.7 300 ppm
	I1-12	100%	100%	100%
	WO 2021/037614 P46	25%	0%	50%

Structure	Example	B.1 7.9 ppm	B.3 7.9 ppm	B.6 300 ppm
	I1-13	100%	100%	100%
	WO 2021/037614 P46	0%	50%	0%

## Claims

## 1. Compounds of formula I



I

5 wherein

R<sup>1</sup> is H, OH, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>1</sub>-C<sub>6</sub>-haloalkyl, C<sub>3</sub>-C<sub>6</sub>-cycloalkyl, C<sub>3</sub>-C<sub>6</sub>-halocycloalkyl, C<sub>1</sub>-C<sub>5</sub>-alkoxy, C<sub>2</sub>-C<sub>4</sub>-alkenyl, C<sub>2</sub>-C<sub>4</sub>-alkynyl, C<sub>1</sub>-C<sub>4</sub>-alkyl-C<sub>3</sub>-C<sub>6</sub>-cycloalkyl, C<sub>1</sub>-C<sub>4</sub>-alkyl-C<sub>3</sub>-C<sub>6</sub>-halocycloalkyl, which groups are unsubstituted, or partially or fully substituted with R<sup>11</sup>;

10 or C(=N-R<sup>11</sup>)R<sup>12</sup>, C(O)R<sup>11a</sup>;

R<sup>11</sup> is CN, NO<sub>2</sub>, NR<sup>12</sup>R<sup>13</sup>, C(O)NH<sub>2</sub>, C(S)NH<sub>2</sub>, C(O)OH, OR<sup>14</sup>, Si(CH<sub>3</sub>)<sub>3</sub>; C<sub>1</sub>-C<sub>6</sub>-alkyl; C<sub>1</sub>-C<sub>6</sub>-haloalkyl; C<sub>2</sub>-C<sub>6</sub>-alkenyl; C<sub>2</sub>-C<sub>6</sub>-haloalkenyl; C<sub>2</sub>-C<sub>6</sub>-alkynyl; C<sub>2</sub>-C<sub>6</sub>-haloalkynyl; C<sub>3</sub>-C<sub>4</sub>-cycloalkyl-C<sub>1</sub>-C<sub>2</sub>-alkyl, which ring is unsubstituted or substituted with 1 or 2 halogen; 3- to 6-membered heterocyclyl, which rings are unsubstituted or substituted with R<sup>a</sup>; 5- or 6-membered hetaryl, or phenyl, which rings are unsubstituted or substituted with R<sup>3a</sup>;

15

R<sup>a</sup> halogen, CN, NO<sub>2</sub>, OH, C<sub>1</sub>-C<sub>4</sub>-alkyl, C<sub>1</sub>-C<sub>4</sub>-haloalkyl, C<sub>1</sub>-C<sub>4</sub>-alkoxy-C<sub>1</sub>-C<sub>4</sub>-alkyl, C<sub>1</sub>-C<sub>4</sub>-alkoxy, C<sub>1</sub>-C<sub>4</sub>-haloalkoxy, C<sub>3</sub>-C<sub>4</sub>-cycloalkyl, C<sub>3</sub>-C<sub>4</sub>-halocycloalkyl, S(O)<sub>m</sub>-C<sub>1</sub>-C<sub>4</sub>-alkyl, S(O)<sub>m</sub>-C<sub>1</sub>-C<sub>4</sub>-haloalkyl, S(O)<sub>m</sub>-C<sub>3</sub>-C<sub>4</sub>-cycloalkyl, S(O)<sub>m</sub>-C<sub>3</sub>-C<sub>4</sub>-halocycloalkyl, and oxo;

20

R<sup>11a</sup> is NR<sup>12</sup>R<sup>13</sup>, C(O)NH<sub>2</sub>, C(S)NH<sub>2</sub>, C(O)OH, OR<sup>14</sup>, Si(CH<sub>3</sub>)<sub>3</sub>; C<sub>1</sub>-C<sub>6</sub>-haloalkyl; C<sub>2</sub>-C<sub>6</sub>-alkenyl; C<sub>2</sub>-C<sub>6</sub>-haloalkenyl; C<sub>2</sub>-C<sub>6</sub>-alkynyl; C<sub>2</sub>-C<sub>6</sub>-haloalkynyl; C<sub>3</sub>-C<sub>4</sub>-cycloalkyl-C<sub>1</sub>-C<sub>2</sub>-alkyl, which ring is unsubstituted or substituted with 1 or 2 halogen; 3- to 6-membered heterocyclyl, which rings are unsubstituted or substituted with R<sup>a</sup>;

25

R<sup>12</sup>, R<sup>13</sup> are independently from each other H, C<sub>1</sub>-C<sub>4</sub>-alkyl, C<sub>1</sub>-C<sub>4</sub>-alkoxy, C<sub>1</sub>-C<sub>4</sub>-haloalkoxy, C<sub>1</sub>-C<sub>4</sub>-haloalkyl, C<sub>3</sub>-C<sub>6</sub>-cycloalkyl, C(O)-C<sub>1</sub>-C<sub>4</sub>-alkyl, C(O)-C<sub>1</sub>-C<sub>4</sub>-haloalkyl, C(O)-C<sub>3</sub>-C<sub>4</sub>-cycloalkyl, C(O)-C<sub>3</sub>-C<sub>4</sub>-halocycloalkyl, C(O)NR<sup>12</sup>R<sup>13</sup>, S(O)<sub>m</sub>-C<sub>1</sub>-C<sub>4</sub>-haloalkyl, S(O)<sub>m</sub>-C<sub>3</sub>-C<sub>4</sub>-cycloalkyl, S(O)<sub>m</sub>-C<sub>3</sub>-C<sub>4</sub>-halocycloalkyl; 3- to 6-membered heterocyclyl, which rings are unsubstituted or substituted with R<sup>a</sup>; 5- or 6-membered hetaryl, or phenyl, which rings are unsubstituted or substituted with R<sup>3a</sup>; or

30

R<sup>12</sup> and R<sup>13</sup>, together with the nitrogen atom to which they are bound, form a 3-, 4-,

5- , 6- or 7-membered saturated, partially unsaturated or fully unsaturated heterocycle, which hetero-cycle may additionally contain 1 or 2 heteroatoms or heteroatom groups selected from N, O, and S(O)<sub>m</sub> as ring members, and which heterocycle is unsubstituted or substituted with one or more substituents selected from R<sup>a</sup>;

R<sup>121</sup> and R<sup>131</sup> are independently from each other H, C<sub>1</sub>-C<sub>4</sub>-alkyl, C<sub>1</sub>-C<sub>4</sub>-haloalkyl, C<sub>3</sub>-C<sub>6</sub>-cycloalkyl, C<sub>3</sub>-C<sub>6</sub>-halocycloalkyl, C<sub>1</sub>-C<sub>4</sub>-alkoxy, C<sub>1</sub>-C<sub>4</sub>-haloalkoxy; C<sub>1</sub>-C<sub>4</sub>-alkyl-phenyl, C<sub>1</sub>-C<sub>4</sub>-alkyl-3-6-membered hetaryl, phenyl, 3- to 6-membered heterocyclyl, which rings are unsubstituted or substituted with R<sup>a</sup>; or 5- or 6-membered hetaryl which rings are unsubstituted or substituted with R<sup>3a</sup>; or

R<sup>121</sup> and R<sup>131</sup> together with the nitrogen atom they are bound to form a 3-6 membered saturated, partially or fully unsaturated heterocycle, which may further contain 1 or 2 heteroatoms ring members selected from N, O and S, wherein S may be oxidized, which heterocycle is unsubstituted or substituted with R<sup>a</sup>;

m is 0, 1, or 2;

R<sup>14</sup> is H, C<sub>1</sub>-C<sub>4</sub>-alkyl, C<sub>1</sub>-C<sub>4</sub>-haloalkyl, C<sub>3</sub>-C<sub>6</sub>-cycloalkyl, C<sub>3</sub>-C<sub>6</sub>-halocycloalkyl, C<sub>3</sub>-C<sub>4</sub>-cycloalkyl-C<sub>1</sub>-C<sub>2</sub>-alkyl, C<sub>3</sub>-C<sub>4</sub>-halocycloalkyl-C<sub>1</sub>-C<sub>2</sub>-alkyl, C(O)-C<sub>1</sub>-C<sub>4</sub>-alkyl, C(O)-C<sub>1</sub>-C<sub>4</sub>-haloalkyl, C(O)-C<sub>3</sub>-C<sub>4</sub>-cycloalkyl, C(O)-C<sub>3</sub>-C<sub>4</sub>-halocycloalkyl, or phenyl which is unsubstituted or partially or fully substituted with R<sup>3a</sup>;

R<sup>2</sup> is H, CN, C<sub>1</sub>-C<sub>3</sub>-alkyl, C<sub>1</sub>-C<sub>3</sub>-haloalkyl, C<sub>2</sub>-C<sub>3</sub>-alkenyl, C<sub>2</sub>-C<sub>3</sub>-alkynyl;

X is CH, CR<sup>3</sup>, or N;

R<sup>3</sup> is halogen, CN, NO<sub>2</sub>, C<sub>1</sub>-C<sub>4</sub>-alkyl, C<sub>3</sub>-C<sub>6</sub>-cycloalkyl, C<sub>1</sub>-C<sub>6</sub>-haloalkyl, C<sub>1</sub>-C<sub>6</sub>-halocycloalkyl, OR<sup>14</sup>, S(O)<sub>m</sub>-R<sup>14</sup>; which are unsubstituted or substituted with R<sup>3a</sup>;

R<sup>3a</sup> halogen, CN, NO<sub>2</sub>, OH, C<sub>1</sub>-C<sub>4</sub>-alkyl, C<sub>1</sub>-C<sub>4</sub>-haloalkyl, C<sub>1</sub>-C<sub>4</sub>-alkoxy-C<sub>1</sub>-C<sub>4</sub>-alkyl, C<sub>1</sub>-C<sub>4</sub>-alkoxy, C<sub>1</sub>-C<sub>4</sub>-haloalkoxy, C<sub>3</sub>-C<sub>4</sub>-cycloalkyl, C<sub>3</sub>-C<sub>4</sub>-halocycloalkyl, S(O)<sub>m</sub>-C<sub>1</sub>-C<sub>4</sub>-alkyl, S(O)<sub>m</sub>-C<sub>1</sub>-C<sub>4</sub>-haloalkyl, S(O)<sub>m</sub>-C<sub>3</sub>-C<sub>4</sub>-cycloalkyl, S(O)<sub>m</sub>-C<sub>3</sub>-C<sub>4</sub>-halocycloalkyl;

n is 0, 1, 2, or 3;

R<sup>4</sup> is OR<sup>14</sup>, CN, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>3</sub>-C<sub>6</sub>-cycloalkyl, C<sub>1</sub>-C<sub>6</sub>-haloalkyl, C<sub>1</sub>-C<sub>6</sub>-halocycloalkyl, C<sub>2</sub>-C<sub>4</sub>-alkenyl, C<sub>2</sub>-C<sub>4</sub>-haloalkenyl, C<sub>2</sub>-C<sub>4</sub>-alkynyl, each unsubstituted or partially or fully substituted with R<sup>41</sup>;

S(O)<sub>m</sub>-C<sub>1</sub>-C<sub>4</sub>-alkyl, S(O)<sub>m</sub>-C<sub>1</sub>-C<sub>4</sub>-haloalkyl, S(O)<sub>m</sub>-C<sub>3</sub>-C<sub>4</sub>-cycloalkyl, S(O)<sub>m</sub>-C<sub>3</sub>-C<sub>4</sub>-halocycloalkyl, NR<sup>12</sup>R<sup>13</sup>, C(O)NR<sup>12</sup>R<sup>13</sup>, C(O)OR<sup>14</sup>, 3- to 6-membered heterocyclyl, which rings are unsubstituted or substituted with R<sup>a</sup>; 5- or 6-membered hetaryl, or phenyl, which rings are unsubstituted or partially or fully substituted with R<sup>3</sup>;

- $R^{41}$  is H, OR<sup>15</sup>, NR<sup>12</sup>R<sup>13</sup>, C<sub>1</sub>-C<sub>4</sub>-alkyl, C<sub>1</sub>-C<sub>4</sub>-haloalkyl, C<sub>3</sub>-C<sub>6</sub>-cycloalkyl, C(O)-C<sub>1</sub>-C<sub>4</sub>-alkyl, C(O)-C<sub>1</sub>-C<sub>4</sub>-haloalkyl, C(O)-C<sub>3</sub>-C<sub>4</sub>-cycloalkyl, C(O)-C<sub>3</sub>-C<sub>4</sub>-halocycloalkyl, C(O)NR<sup>121</sup>R<sup>131</sup>;  
S(O)<sub>m</sub>-C<sub>1</sub>-C<sub>4</sub>-haloalkyl, S(O)<sub>m</sub>-C<sub>3</sub>-C<sub>4</sub>-cycloalkyl, S(O)<sub>m</sub>-C<sub>3</sub>-C<sub>4</sub>-halocycloalkyl; 3- to 6-membered heterocyclyl, 5- or 6-membered hetaryl, or phenyl;  
which non-aromatic cyclic R<sup>41</sup> groups are unsubstituted or partially or fully substituted with R<sup>a</sup>;  
which aromatic R<sup>41</sup> groups are unsubstituted or partially or fully substituted with R<sup>3a</sup>;
- $R^{15}$  is H, C<sub>1</sub>-C<sub>4</sub>-alkyl, or C<sub>1</sub>-C<sub>4</sub>-haloalkyl, C<sub>3</sub>-C<sub>6</sub>-cycloalkyl, C<sub>1</sub>-C<sub>6</sub>-halocycloalkyl, which carbon chains are unsubstituted or partially or fully substituted with R<sup>11</sup>; or 3- to 6-membered heterocyclyl, which rings are unsubstituted or substituted with R<sup>a</sup>; 5- or 6-membered hetaryl, or phenyl, which rings are unsubstituted or partially or fully substituted with R<sup>3a</sup>;
- and the N-oxides, stereoisomers and agriculturally or veterinarily acceptable salts thereof.
2. Compounds of formula I according to claim 1, wherein
- $R^{11}$  is CN, NO<sub>2</sub>, NR<sup>12</sup>R<sup>13</sup>, C(O)NH<sub>2</sub>, C(S)NH<sub>2</sub>, C(O)OH, OR<sup>14</sup>, Si(CH<sub>3</sub>)<sub>3</sub>; C<sub>1</sub>-C<sub>6</sub>-alkyl; C<sub>1</sub>-C<sub>6</sub>-haloalkyl; C<sub>2</sub>-C<sub>6</sub>-alkenyl; C<sub>2</sub>-C<sub>6</sub>-haloalkenyl; C<sub>2</sub>-C<sub>6</sub>-alkynyl; C<sub>2</sub>-C<sub>6</sub>-haloalkynyl; C<sub>3</sub>-C<sub>4</sub>-cycloalkyl-C<sub>1</sub>-C<sub>2</sub>-alkyl, which ring is unsubstituted or substituted with 1 or 2 halogen; 3- to 6-membered heterocyclyl, 5- or 6-membered hetaryl, or phenyl, which rings are unsubstituted or substituted with halogen, C<sub>1</sub>-C<sub>3</sub>-haloalkyl, and/or CN;
- $R^{11a}$  is NR<sup>12</sup>R<sup>13</sup>, C(O)NH<sub>2</sub>, C(S)NH<sub>2</sub>, C(O)OH, OR<sup>14</sup>, Si(CH<sub>3</sub>)<sub>3</sub>; C<sub>1</sub>-C<sub>6</sub>-haloalkyl; C<sub>2</sub>-C<sub>6</sub>-alkenyl; C<sub>2</sub>-C<sub>6</sub>-haloalkenyl; C<sub>2</sub>-C<sub>6</sub>-alkynyl; C<sub>2</sub>-C<sub>6</sub>-haloalkynyl; C<sub>3</sub>-C<sub>4</sub>-cycloalkyl-C<sub>1</sub>-C<sub>2</sub>-alkyl, which ring is unsubstituted or substituted with 1 or 2 halogen; 3- to 6-membered heterocyclyl, which rings are unsubstituted or substituted with halogen, C<sub>1</sub>-C<sub>3</sub>-haloalkyl, and/or CN;
- $R^{12}$ ,  $R^{13}$  are independently from each other H, C<sub>1</sub>-C<sub>4</sub>-alkyl, C<sub>1</sub>-C<sub>4</sub>-alkoxy, C<sub>1</sub>-C<sub>4</sub>-haloalkoxy, C<sub>1</sub>-C<sub>4</sub>-haloalkyl, C<sub>3</sub>-C<sub>6</sub>-cycloalkyl, C(O)-C<sub>1</sub>-C<sub>4</sub>-alkyl, C(O)-C<sub>1</sub>-C<sub>4</sub>-haloalkyl, C(O)-C<sub>3</sub>-C<sub>4</sub>-cycloalkyl, C(O)-C<sub>3</sub>-C<sub>4</sub>-halocycloalkyl, C(O)NR<sup>121</sup>R<sup>131</sup>, S(O)<sub>m</sub>-C<sub>1</sub>-C<sub>4</sub>-haloalkyl, S(O)<sub>m</sub>-C<sub>3</sub>-C<sub>4</sub>-cycloalkyl, S(O)<sub>m</sub>-C<sub>3</sub>-C<sub>4</sub>-halocycloalkyl; 3- to 6-membered heterocyclyl, 5- or 6-membered hetaryl, or phenyl, which rings are unsubstituted or substituted with halogen, C<sub>1</sub>-C<sub>3</sub>-haloalkyl, and/or CN;
- $R^{121}$  and  $R^{131}$  are independently from each other hydrogen, C<sub>1</sub>-C<sub>4</sub>-alkyl, C<sub>1</sub>-C<sub>4</sub>-haloalkyl, C<sub>3</sub>-C<sub>6</sub>-cycloalkyl, C<sub>3</sub>-C<sub>6</sub>-halocycloalkyl, C<sub>1</sub>-C<sub>4</sub>-alkoxy, C<sub>1</sub>-C<sub>4</sub>-haloalkoxy; C<sub>1</sub>-C<sub>4</sub>-alkyl-phenyl, C<sub>1</sub>-C<sub>4</sub>-alkyl-3-6-membered hetaryl, phenyl, 3- to 6-membered heterocyclyl or 5- or 6-membered hetaryl which rings are unsubstituted or substituted with halogen,

C<sub>1</sub>-C<sub>3</sub>-haloalkyl, and/or CN; or

R<sup>121</sup> and R<sup>131</sup> together with the nitrogen atom they are bound to form a 3-6 membered saturated, partially or fully unsaturated heterocycle, which may further contain 1 or 2 heteroatoms ring members selected from N, O and S, wherein S may be oxidized, which heterocycle is unsubstituted or substituted with halogen, C<sub>1</sub>-C<sub>3</sub>-haloalkyl, and/or CN;

R<sup>14</sup> is H, C<sub>1</sub>-C<sub>4</sub>-alkyl, C<sub>1</sub>-C<sub>4</sub>-haloalkyl, C<sub>3</sub>-C<sub>6</sub>-cycloalkyl, C<sub>3</sub>-C<sub>6</sub>-halocycloalkyl, C<sub>3</sub>-C<sub>4</sub>-cycloalkyl-C<sub>1</sub>-C<sub>2</sub>-alkyl, C<sub>3</sub>-C<sub>4</sub>-halocycloalkyl-C<sub>1</sub>-C<sub>2</sub>-alkyl, C(O)-C<sub>1</sub>-C<sub>4</sub>-alkyl, C(O)-C<sub>1</sub>-C<sub>4</sub>-haloalkyl, C(O)-C<sub>3</sub>-C<sub>4</sub>-cycloalkyl, C(O)-C<sub>3</sub>-C<sub>4</sub>-halocycloalkyl, or phenyl which is unsubstituted or partially or fully substituted with R<sup>3</sup>;

R<sup>2</sup> is H, CN, C<sub>1</sub>-C<sub>3</sub>-alkyl, C<sub>1</sub>-C<sub>3</sub>-haloalkyl, C<sub>2</sub>-C<sub>3</sub>-alkynyl;

R<sup>4</sup> is H, OH, CN, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>3</sub>-C<sub>6</sub>-cycloalkyl, C<sub>1</sub>-C<sub>6</sub>-haloalkyl, C<sub>1</sub>-C<sub>6</sub>-halocycloalkyl, C<sub>2</sub>-C<sub>4</sub>-alkenyl, C<sub>2</sub>-C<sub>4</sub>-haloalkenyl, C<sub>2</sub>-C<sub>4</sub>-alkynyl, C<sub>1</sub>-C<sub>4</sub>-alkoxy, C<sub>1</sub>-C<sub>4</sub>-haloalkoxy, each unsubstituted or partially or fully substituted with R<sup>41</sup>;

S(O)<sub>m</sub>-C<sub>1</sub>-C<sub>4</sub>-alkyl, S(O)<sub>m</sub>-C<sub>1</sub>-C<sub>4</sub>-haloalkyl, S(O)<sub>m</sub>-C<sub>3</sub>-C<sub>4</sub>-cycloalkyl, S(O)<sub>m</sub>-C<sub>3</sub>-C<sub>4</sub>-halocycloalkyl, NR<sup>12R13</sup>, C(O)NR<sup>12R13</sup>, C(O)OR<sup>14</sup>, 3- to 6-membered heterocyclyl, 5- or 6-membered hetaryl, or phenyl, which rings are unsubstituted or partially or fully substituted with R<sup>3</sup>;

R<sup>41</sup> is H, OR<sup>15</sup>, NR<sup>12R13</sup>, C<sub>1</sub>-C<sub>4</sub>-alkyl, C<sub>1</sub>-C<sub>4</sub>-haloalkyl, C<sub>3</sub>-C<sub>6</sub>-cycloalkyl, C(O)-C<sub>1</sub>-C<sub>4</sub>-alkyl, C(O)-C<sub>1</sub>-C<sub>4</sub>-haloalkyl, C(O)-C<sub>3</sub>-C<sub>4</sub>-cycloalkyl, C(O)-C<sub>3</sub>-C<sub>4</sub>-halocycloalkyl, C(O)NR<sup>121R131</sup>;

S(O)<sub>m</sub>-C<sub>1</sub>-C<sub>4</sub>-haloalkyl, S(O)<sub>m</sub>-C<sub>3</sub>-C<sub>4</sub>-cycloalkyl, S(O)<sub>m</sub>-C<sub>3</sub>-C<sub>4</sub>-halocycloalkyl; 3- to 6-membered heterocyclyl, 5- or 6-membered hetaryl, or phenyl;

which cyclic R<sup>41</sup> groups are unsubstituted or partially or fully substituted with halogen, C<sub>1</sub>-C<sub>3</sub>-haloalkyl, and/or CN;

R<sup>15</sup> is H, C<sub>1</sub>-C<sub>4</sub>-alkyl, or C<sub>1</sub>-C<sub>4</sub>-haloalkyl, C<sub>3</sub>-C<sub>6</sub>-cycloalkyl, C<sub>1</sub>-C<sub>6</sub>-halocycloalkyl, which carbon chains are unsubstituted or partially or fully substituted with R<sup>11</sup>; or 3- to 6-membered heterocyclyl, 5- or 6-membered hetaryl, or phenyl, which rings are unsubstituted or partially or fully substituted with R<sup>3</sup>;

and the N-oxides, stereoisomers and agriculturally or veterinarily acceptable salts thereof.


3. Compounds of formula I according to claim 1 or 2, wherein R<sup>1</sup> is H.

4. Compounds of formula I according to any of claim 1 to 3, wherein R<sup>2</sup> is CH<sub>3</sub>.


5. Compounds of formula I according to any of claim 1 to 4, wherein R<sup>3</sup> is halogen, CN, C<sub>1</sub>-C<sub>4</sub>-haloalkyl, C<sub>1</sub>-C<sub>4</sub>-haloalkoxy, C<sub>3</sub>-C<sub>4</sub>-cycloalkyl unsubstituted or substituted with one or

more CN, C<sub>3</sub>-C<sub>4</sub>-halocycloalkyl, S(O)<sub>m</sub>-C<sub>1</sub>-C<sub>4</sub>-alkyl, S(O)<sub>m</sub>-C<sub>1</sub>-C<sub>4</sub>-haloalkyl, S(O)<sub>m</sub>-C<sub>3</sub>-C<sub>4</sub>-cycloalkyl, S(O)<sub>m</sub>-C<sub>3</sub>-C<sub>4</sub>-halocycloalkyl, or S(O)<sub>m</sub>-R<sup>14</sup>, wherein R<sup>14</sup> is phenyl, which is partially substituted with R<sup>3a</sup>.

- 5 6. Compounds of formula I according to any of claim 1 to 5, wherein n is 2 and R<sup>3</sup> is in positions 3 and 5.
7. Compounds of formula I according to any one of claims 1 to 6, wherein X is CH.
- 10 8. Compounds of formula I according to any one of claims 1 to 6, wherein X is N.
9. Compounds of formula I according to any one of claims 1 to 8, wherein R<sup>4</sup> is H, C<sub>1</sub>-C<sub>3</sub>-alkyl, C<sub>1</sub>-C<sub>3</sub>-haloalkyl, C<sub>1</sub>-C<sub>4</sub>-alkoxy-C<sub>1</sub>-C<sub>4</sub>-alkyl, CH<sub>2</sub>C(O)NH-C<sub>1</sub>-C<sub>6</sub>-alkyl, S(O)<sub>m</sub>-C<sub>1</sub>-C<sub>4</sub>-alkyl, or phenyl unsubstituted or substituted with one or more groups R<sup>3</sup> as defined in claim 5.
- 15 10. Compounds of formula I according to any one of the preceding claims, which consist mainly of the isomer I.A.



- 20 11. Intermediate compounds of formula Int, wherein the variables are defined for formula I according to any one of the preceding claims.



- 25 12. An agricultural or veterinary composition comprising at least one compound according to any one of claims 1 to 10 and/or at least one agriculturally or veterinarily acceptable salt thereof, and at least one inert liquid and/or solid agriculturally or veterinarily acceptable carrier.

13. An agricultural composition for combating animal pests comprising at least one compound as defined in any of claims 1 to 10 and at least one inert liquid and/or solid acceptable carrier and, if desired, at least one surfactant.
- 5 14. A method for combating or controlling invertebrate pests, which method comprises contacting said pest or its food supply, habitat or breeding grounds with a pesticidally effective amount of at least one compound as defined in any one of claims 1 to 10.
- 10 15. A method for protecting growing plants from attack or infestation by invertebrate pests, which method comprises contacting a plant, or soil or water in which the plant is growing, with a pesticidally effective amount of at least one compound as defined in any of claims 1 to 10.
- 15 16. Seed comprising a compound as defined in any of claims 1 to 10, or the enantiomers, diastereomers or salts thereof, in an amount of from 0.1 g to 10 kg per 100 kg of seed.
- 20 17. A method for treating or protecting an animal from infestation or infection by invertebrate pests which comprises bringing the animal in contact with a pesticidally effective amount of at least one compound of the formula I as defined in any of claims 1 to 10, a stereoisomer thereof and/or at least one veterinarily acceptable salt thereof.

**INTERNATIONAL SEARCH REPORT**

International application No  
**PCT/EP2022/072821**

**A. CLASSIFICATION OF SUBJECT MATTER**  
**INV. C07D401/14 C07D403/04 A01N43/653**  
**ADD.**

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**  
 Minimum documentation searched (classification system followed by classification symbols)  
**C07D A01N**

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
**EPO-Internal, WPI Data, CHEM ABS Data**

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
<b>X</b>	<b>WO 2021/037614 A1 (SYNGENTA CROP PROTECTION AG [CH]) 4 March 2021 (2021-03-04) cited in the application page 110, table I, intermediate compound I4; claims</b>	<b>1-17</b>
<b>X</b>	<b>WO 2021/122645 A1 (SYNGENTA CROP PROTECTION AG [CH]) 24 June 2021 (2021-06-24) cited in the application page 16, line 23; claims; examples</b>	<b>1-17</b>

Further documents are listed in the continuation of Box C.       See patent family annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search  <b>17 November 2022</b>	Date of mailing of the international search report  <b>28/11/2022</b>
--	---

Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer  <b>Beyss-Kahana, Ellen</b>
--	--

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2022/072821

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
<b>WO 2021037614 A1</b>	<b>04-03-2021</b>	<b>BR 112022003375 A2</b>	<b>17-05-2022</b>
		<b>CN 114269732 A</b>	<b>01-04-2022</b>
		<b>EP 4017851 A1</b>	<b>29-06-2022</b>
		<b>JP 2022545266 A</b>	<b>26-10-2022</b>
		<b>TW 202112238 A</b>	<b>01-04-2021</b>
		<b>US 2022289715 A1</b>	<b>15-09-2022</b>
		<b>WO 2021037614 A1</b>	<b>04-03-2021</b>
-----			
<b>WO 2021122645 A1</b>	<b>24-06-2021</b>	<b>NONE</b>	
-----			